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SYNOPSIS 
Patients with diabetic renal disease develop 
elevated urinary albumin excretion rates [AER] and 
hypertension. Preliminary data from several groups suggest 
that diabetic patients handle transferrin, a protein similar 
in size and weight, in a different fashion from albumin. In 
the first part of this thesis I report the results of 
clinical studies of urinary transferrin excretion [TER] in 
diabetes mellitus. 
More than 8 0 %  type 1 [insulin dependent] diabetic 
patients have increased TER but less than 40% have increased 
AER. TER may be provoked by exercise in uncomplicated type 1 
diabetes and the rise is proportionally far greater than that 
for AER. Newly diagnosed type 2 [non-insulin dependent] 
diabetic subjects have increased TER which falls With 
improved glycaemic control. Interventional studies with 
lisinopril, an angiotensin converting enzyme [ACE] inhibitor, 
in microalbuminuric and macroalbuminuric diabetic subjects 
show a reduction in TER independent of reduction in blood 
pressure. Data are presented suggesting a role for altered 
renal tubular function in TER in diabetes. 
The second part of the thesis examines the role of 
the system in the hypertension 
of diabetic renal disease. Patients with elevated AER have 
increased resting plasma renin activity. Those with 
uncomplicated diabetes show an exaggerated blood pressure 
reponse to exercise. ACE inhibition reduces blood pressure 
in hypertensive patients and AER in both hypertensive and 
normotensive patients. 
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AIMS OF THE THESIS 
part 1. 
1. TO investigate the utility of measurement of urinary 
transferrin excretion as a marker for renal disease in 
diabetes mellitus. This aim to be achieved by a series of 
clinical studies: 
i. To establish the prevalence of diabetic renal disease 
[defined by the presence of elevated urinary albumin 
pxcretion rate] in a defined clinic population. 
ii. To establish the prevalence of elevated urinary 
transferrin excretion in the same population. 
ii. To examine the influence of glycaemic control on 
transferrin excretion. 
iv .  To examine the influence of exercise on transferrin 
excretion. 
v. To examine the influence of angiotensin converting 
enzyme [ACE] inhibition on transferrin excretion. 
2. By means of these studies to offer an explanation for 
differences in behaviour between transferrin and albumin in 
diabetes. 
part 2. 
1. To study the role of the Renin-Angiotensin-Aldosterone 
System in the hypertension of diabetic renal disease; at rest 
and in exercise. 
2. TO study the influence of angiotensin converting enzyme 
[ACE] inhibition on hypertension and the progression of renal 
disease in diabetes mellitus. 
PERSONAL CONTRIBUTION TO THE THESIS 
I personally conceived the idea for each of the 
studies described in this thesis. 
Over the course of 12 months I examined every type 
1 diabetic patient from the clinic at East Birmingham 
Hospital and organised urine collections from them to screen 
for diabetic nephropathy. I performed autonomic function 
testing on them all and analysed the results. This 
population was subsequently screened for transferrinuria. 
I recruited and examined normal subjects from 
among the hospital staff who acted as controls for estimation 
of transferrin excretion. 
I devised the study protocol and, with the help 
of Dr John Watson [Registrar], recruited and studied newly 
diagnosed type 2 diabetic patients referred to clinic. Each 
patient was examined and urine collections were made on three 
occasions. 
I recruited and, with the help of Dr David Cavan 
[Registrar], exercise tested normal control and uncomplicated 
type 1 diabetic subjects. 
I devised two major studies involving the use of 
angiotensin converting enzyme [ACE] inhibitors in diabetic 
nephropathy. These were both double blind and single 
centre. To date these remain the largest studies of their 
kind in the world. I performed all the measurements of 
renal blood flow and glomerular filtration myself - giving 
the radioisotopes and taking blood samples as necessary. This 
also involved the organisation of two timetables to 
coordinate trial visits for both studies, the collection of 
data, and maintenance of the trial record books. 
With the exception of data presented in chapters 
11 and 12 [performed by ICI Pharamceuticals] I have analysed 
all data myself. Much of the data presented in this thesis 
has been published in medical and scientific journals and 
reprints of these papers are appended. 
CHAPTER 1 
DIABETIC NEPHROPATHY - LITERATURE REVIEW 
1 
DIABETIC NEPHROPATHY 
Diabetes mellitus is a common condition which affects 
approximately 1% of the population in the United Kingdom. The 
hyperglycaemia of diabetes is thought to be responsible fo r  
the recognized complications of retinopathy, neuropathy and 
nephropathy. 
1.1. Definition of Diabetic Nephropathy 
The traditional clinical definition of diabetic 
nephropathy rests upon the observation of a mean urinary 
protein excretion rate greater than 0 . 5  g in at least 3 
collections in a patient who has been diabetic for more than 
10 years [Mogensen 1988a]. Diabetic nephropathy is 
characterised by morphological and functional alterations in 
the kidney. These changes, however, do not necessarily occur 
in parallel: histological changes may be present in the 
absence of proteinuria [Deckert et al 19851. Mauer et al 
I19841 studied 45 type 1 diabetic patients and found no 
correlation between histological abnormality and degree of 
proteinuria. 
1.1.1. Renal Morphology 
The classical histological lesion of diabetic 
nephropathy is- glomerulosclerosis as described by Kimmelsteil 
and Wilson [1936]. Within this description there are five 
lesions which may occur in variable combinations; a diffuse 
lesion with uniform mesangial expansion; a nodular lesion 
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where the mesangial matrix takes a globular shape; a fibrinoid 
cap which has a crescentic shape and is situated in the 
peripheral capillary wall; a capsular drop situated on the 
inner side of the capsule of Bowman; arteriolar hyalinosis in 
which eosinophilic material collects in the walls of the 
afferent and efferent arterioles. The thrust of this thesis, 
however, deals with the functional abnormalities found in 
diabetic nephropathy. 
1.1.2. Renal Function 
Renal function in diabetic nephropathy passes through 
five stages as defined by Mogensen [Table 1.1]. Briefly, the 
stages may be described as follows: 
Stage 1. 
Glomerular hyperfunction and hypertrophy. This is present 
at diagnosis. 
Silent stage with normal albumin excretion but structural 
lesions present. This may persist for many years and be 
revealed only as increased AER in times of stress e.g. under 
exercise provocation. 
Stage 2. 
Stage 3 .  
Incipient nephropathy with persistent microalbuminuria and 
systemic blood pressure levels which although not frankly 
hypertensive are higher than those of matched subjects 
without proteinuria. 
Stage 4 .  
Overt, or frank, nephropathy - characterised by 
macroalbuminuria, systemic hypertension and falling GFR. 
Stage 5 .  
End stage renal failure. 
[Mogensen and Schmitz 1988b] 
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1.2.1. Prevalence of Overt Diabetic Nephropathy 
The true prevalence of diabetic nephropathy is unknown 
since population based studies have not been performed. In 
selected patient groups, however, nephropathy has been 
reported to affect as many as 40% of type 1 [insulin 
dependent] diabetic patients [Andersen et al 1983, Krolewski 
et al 1985, Borch-Johnsen et al 1986] although this figure may 
be declining [Kofoed-Enevoldsen et al 1987]. A similar 
proportion of type 2 [non-insulin dependent] patients may 
suffer from nephropathy [Kunzelman et al 1985, Sasaki et al 
1986] although many workers have reported lower prevalence 
figures for this group of patients. Two studies from this 
country reported prevalences of and 2.7% [Daggett 1986] and 
6.8% [Gatling et al 1987]. A population based study from 
Rochester, Minnesota found a cumulative incidence of 
persistent proteinuria of 24.6% after twenty years' disease 
[Ballard et al 1988]. 
1.2.2. Prevalence of Incipient Diabetic Nephropathy 
Microalbuminuria, now conventionally defined as AER 
between 20 and 200 predicts the development 
Of diabetic nephropathy [Viberti et al 1982, Mathiesen et al 
1984] and has been used as a measure of prevalence for 
nephropathy. The reports quote prevalence figures of 20% 
[Mathiesen et al 1986], 10.7% [Mills and Hocken 1986], 23% 
[Niazy et al 1987], 16% [Berglund et al 1987] and 22% [Parving 
et al 1988a]. These results, however, are confounded by the 
fact that not only did the patients have different disease 
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durations but also the studies were performed before there was 
a standard definition of microalbuminuria. Hence, each group 
adopted its own definition - AER greater than 15 
[Mogensen and Christensen 1984a], between 30 and 140 
[Viberti et al 1982], greater than 70 
[Mathiesen et al 1984], and between 30 mg and 300 mg 
[Niazy et al 1987, Parving et al 1988a]. 
There appears to be a bimodal prevalence of nephropathy 
with peaks at 20-40 years and 60 years of age [Bjerkelund 
1951, MacNeal and Rogers 1955, El Mahallawy and Sabour 1960]. 
The earlier peak probably represents those patients with type 
1 and the latter those with type 2 disease. 
1.3. Morbidity and Mortality 
Patients with type 1 [insulin dependent] diabetes 
mellitus have a mortality rate up to twenty times higher than 
the non diabetic population [Borch-Johnsen et al 1986]. This 
excess has been ascribed predominantly to cardiovascular 
disease which may account for 50% of deaths [Kessler 1971], 
and renal disease which accounts for a similar proportion 
[Moloney et al 1983, Andersen et al 1983]. Patients who do 
not develop persistent proteinuria have a relative mortality 
about twice that of the general population whereas those with 
proteinuria have an absolute mortality rate of 17% per year 
[Borch-Johnsen et al 1985]. Mortality from renal disease shows 
a positive correlation with the duration of persistent 
proteinuria. In an early study five year survival after 
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onset of persistent proteinuria was 65% but the corresponding 
figure at 10 years was only 28% [Caird 1961]. A more recent 
study, however, suggests that mortality may be falling and 
that this may be because of a fall in the prevalence of 
nephropathy [Borch-Johnsen et al 1986]. 
It is estimated that nearly 600 patients per year in the 
United Kingdom will develop end stage renal failure as a 
consequence of diabetes mellitus [Joint Working Party on 
Diabetic Renal Failure 1985]. In the United States diabetes 
accounted for 24.5% of new cases of renal failure due to end 
stage renal disease in 1984 [Sepe and Teutsch 1988]. A study 
of Scandinavian diabetic patients reported 51% survival seven 
years after the development of overt nephropathy [Andersen et 
al 1983] while in the United Kingdom there was only a 49% 
survival at three years for patients with end-stage renal 
disease as a consequence of diabetes [Cameron and Challah 
1986]. 
Microalbuminuria, an early marker for diabetic renal 
disease, is a predictor of increased mortality especially in 
type 2 [non-insulin dependent] diabetes [Mogensen 1984b, 
Jarrett et al 1984]. In a 10 year follow up study of more 
than 400 type 2 diabetic patients with microalbuminuria 56% 
died from cardiovascular causes but less than 3% from renal 
failure [Mogensen et al 1985]. This may be a manifestation 
of the increased large vessel disease to which [elderly] type 
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2 diabetic patients are prone. 
Hypertension has been recognized to be a complication of 
diabetes for many years [Hintzenberger 1921]. An increase in 
the body's exchangeable sodium is thought to be responsible 
for the increase in blood pressure. Normotensive diabetic 
patients without nephropathy have increased exchangeable body 
sodium compared with non-diabetic control subjects and 
hypertensive diabetic patients with nephropathy have even 
higher levels [O'Hare et al 1985]. 
1.4. Factors involved in the development of diabetic 
nephropathy. 
Factors which may be involved in the development and 
progression of diabetic nephropathy are race, sex, metabolic 
state, dietary protein and systemic blood pressure. 
1.4.1. Race and Sex. 
Race and gender may be risk factors since Native and 
Afro-Americans are at increased risk of nephropathy [Waring 
1970, West 1974, Friedman 1987] and some workers have reported 
an increased prevalence in males [Andersen et al 1978, West et 
al 1980]. It has been reported recently that Afro-Americans 
have an increased incidence of end-stage diabetic renal 
disease compared with white Americans [Cowie et al 1989]. The 
Afro-Americans, however, had higher systemic blood pressures 
than the white hence it is unclear whether the increased 
incidence of renal disease was a consequence of this or race. 
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1.4.2. Metabolic State. 
It should be self-evident that diabetic nephropathy does 
not occur in the absence of diabetes. However, a direct 
causative link between hyperglycaemia and the development of 
diabetic nephropathy in humans remains to be established 
[Larkins and Dunlop 1992]. In a study of 292  type 1 diabetic 
patients followed between 20 and 40 years from diagnosis, 
those with the worst glycaemic control [highest blood sugars] 
during the first 15 years of their disease had more than four 
times the risk of developing nephropathy as those with good 
glycaemic control [Krolewski et al 1985]. Chase and co 
workers [1989] reported 3 . 6  times the prevalence of 
microalbuminuria in patients with poor glycaemic control 
compared with those with good control in a study of 230  type 1 
diabetic subjects. A population based study of the Nauru 
islanders, who have a high prevalence of impaired glucose 
tolerance and type 2 diabetes, identified blood glucose and 
blood pressure as risk factors for the development of micro- 
and macroalbuminuria [Collins et al 1989]. 
1.4.2.1. Improved Glycaemic Control 
Improved glycaemic control has been demonstrated to 
reduce proteinuria in animal models of diabetes [Pennell et al 
1981] and in a series of papers Rasch reported prevention of 
diabetic glomerulopathy in streptozocin diabetic rats treated 
with insulin [Rasch 1979a, 1979b, 1980]. Petersen et al 
[1988] reported that sub-cutaneous insulin therapy could 
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arrest the progress of the disease even after the development 
of glomerular pathology. 
Many studies have addressed the question of whether 
improved metabolic control can prevent or retard the 
progression of nephropathy in human diabetes [Viberti et al 
1983, Kroc Collaborative Study Group 1984, Wiseman et al 1985, 
Feldt-Rasmussen et al 1986, Dahl-Jorgensen et al 1988, Bending 
et al 1986]. The results of these studies, however, have been 
variable. Mauer et al [1989a] studied normal kidneys 
transplanted into patients with type 1 diabetes. They found 
only an imprecise relationship between histological changes of 
diabetic nephropathy in the transplanted kidney and the degree 
of glycaemic control and suggest that in addition to glycaemic 
control there are risk factors intrinsic to the kidney itself. 
There is one report in the literature of kidneys taken from a 
patient with type 1 diabetes and transplanted into nondiabetic 
recipients [Abouna et al 1983]. Renal biopsies seven months 
post transplant showed almost complete resolution of diabetic 
nephropathy indicating that even severe lesions can be 
reversed. Factors other than normoglycaemia, however, may 
have been important. A recent re-examination of patients 
entered into two independent studies at the Steno hospital 
looked at the outcome of patients treated with either 
conventional insulin regimes or insulin infusion [Feldt- 
Rasmussen et al 1991]. This study showed that insulin infusion 
treated patients had better glycaemic control; fewer developed 
frank nephropathy; they had a slower decline in GFR. These 
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results suggest that nearly normalising blood glucose in 
diabetic patients for prolonged periods of time does protect 
against deterioration in renal function. 
There is, as yet, no convincing evidence that tight 
glycaemic control is of major benefit in the long term 
prevention of diabetic nephropathy. 
1.4.3. Dietary Protein. 
Brenner et al [1982] have proposed a mechanism whereby 
high protein intake may stimulate glomerulosclerosis; and 
Mauer et al [1989b] reported increased fractional mesangial 
volume, an abnormality seen in diabetic nephropathy, in 
streptozocin diabetic rats fed high protein diets. Nyberg et 
al [1987] assessed protein intake by dietary history in three 
groups of diabetic patients; those with long standing diabetes 
but no evidence of nephropathy; those with nephropathy and 
reduced but stable GFR; those with progressive renal 
impairment. There was no discernible difference between the 
groups' protein intake and no correlation between protein 
intake and rate of decline in renal function. 
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1.4.3.1. Reduction in Dietary Protein 
Despite the fact that reductions in dietary protein have 
been used for many years to treat renal failure arising from a 
variety of causes there have been only two prospective 
randomised trials of this treatment, neither of them in 
diabetes [Rosman et al 1984, Ihle et al 1989]. The re have 
been no long term studies of dietary protein restriction in 
the treatment of diabetic nephropathy. Medium to short term 
studies in patients with established nephropathy [Evanoff et 
al 1987, Walker et al 1989] and incipient nephropathy [Wiseman 
et al 1987, Cohen et al 1987] report reductions in albuminuria 
and decline of renal function [GFR]. Bending et al [1988], 
however, in a cross-over study comparing usual-protein with 
restricted-protein diets in patients with nephropathy found 
reductions in urinary protein excretion but no change in 
glomerular filtration rate or renal plasma flow on the 
restricted diet. They concluded that the diet had somehow 
altered glomerular permselectivity. Limitation of dietary 
protein in normoalbuminuric diabetic patients appears to 
reduce glomerular hyperfiltration and so offer some protection 
from subsequent nephropathy [Kupin et al 1987, Pedersen et 
al 1989]. There is not, however, enough evidence at the moment 
to implicate dietary protein in the pathogenesis of diabetic 
nephropathy nor to recommend protein restriction to patients 
with this complication. 
1 . 4 . 4 .  Systemic Hypertension 
There is now a considerable body of evidence that raised 
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blood pressure plays a major role in the development and 
progression of diabetic nephropathy and, moreover, that 
lowering blood pressure may affect the rate of disease 
progression. 
1.4.4.1. Aetiology of hypertension in diabetic nephropathy. 
A proportion of diabetic patients may have essential 
[idiopathic] hypertension in association with nephropathy. In 
a study of non-diabetics with essential hypertension and 
diabetics with incipient or overt nephropathy there was 
acorrelation between mean arterial pressure and rate of 
urinary albumin excretion but with considerable overlap 
between the two groups. When the two variables were 
evaluated for each group individually, however, the diabetic 
patients were found to have a mich higher albumin excretion 
rate at any given blood pressure [Christensen et al 1987]. On 
this basis it may be possible to separate patients with 
essential hypertension from those with diabetic nephropathy. 
The majority of patients with diabetic nephropathy will have 
hypertension as consequence of this complication. The 
aetiology of this type of hypertension has not yet been fully 
elucidated but is almost certainly multifactorial and 
dependent upon genetic and hormonal factors. 
1.4.4.2. Genetic influences 
Several recent reports suggest that there is a 
genetically determined tendency to hypertension which may be 
important in the development of diabetic nephropathy. First, 
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hypertension is more common in the hypertensive siblings of 
patients with type 1 or type 2 diabetes than in the siblings 
of those who are normotensive [Kelleher et al 1988]. Second, 
the parents of patients with type 1 diabetes who have 
proteinuria tend to have higher blood pressures than the 
parents of patients who do not develop proteinuria [Viberti et 
al 1987]. The third piece of evidence comes from a study of 
89 patients with type 1 diabetes [Krolewski et al 1988]. At 
recall, approximately 18 years after diagnosis, 33 patients 
had developed diabetic nephropathy. The risk of developing 
nephropathy was tripled if they had a parent with 
hypertension. The patients with nephropathy had increased 
erythrocyte sodium-lithium cotransport. Sodium lithium 
cotransport has been reported to be normal or elevated in 
patients with variable stages of diabetic nephropathy [Mangili 
et al 1988, Jones et al 1990, Carr et al 1990, Elving et al 
1991]. The abnormality has been shown to be associated with 
hypertension [Canessa et al 1980] and may be a marker for its 
heretibility [Canali et al 1981, Walker et al 1990]. A study 
of two groups of diabetic patients, with and without 
nephropathy, and their siblings showed that the siblings of 
nephropaths had increased albumin excretion rates compared 
with siblings of non-nephropaths [Seaquist et al 1989]. In 
this study, however, there was no significant difference in 
blood pressure between the two groups of siblings. Jensen 
et al [1990], however, measured arterial blood pressure and 
maximal sodium-lithium cotransport in the parents of patients 
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with type 1 diabetes with nephropathy, normoalbuminuric 
diabetes and age matched non diabetic controls. They found 
no difference between the blood pressures in the two goups of 
parents. Patients with diabetes had higher sodium-lithium 
cotransport than non-diabetic control subjects independent of 
the presence of nephropathy. Those diabetic patients with 
nephropathy had non-significantly higher [P = 0.06] sodium- 
lithium cotransport than those without. These workers 
conclude that genetic predispostions to hypertension and 
increased nephropathy sodium-lithium cotransport activity are 
not risk markers for the development of diabetic nephropathy. 
1.4.4.3. Volume expansion 
Hypertensive diabetic patients have increased plasma 
volume. The volume increase is mediated by increased 
exchangeable body sodium and these may precede the onset of 
hypertension [De Chatel et al 1977]. Nephropathic diabetics 
have a further increase in their exchangeable sodium compared 
with those who do not have nephropathy [O'Hara et al 1985, 
Feldt-Rasmussen et al 1987]. The reason(s) for the high levels 
of exchangeable sodium are not known, although insulin has 
been shown to promote renal tubular absorption of sodium [De 
Fronzo 1981]. The increased body sodium leads to fluid 
retention and expanded circulating volume hence favouring the 
development of hypertension. 
1 . 4 . 4 . 4 .  Renin-Anqiotensin-Aldosterone System 
The renin-angiotensin-aldosterone system [RAAS] plays a 
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role in the modification of vascular tone and sodium 
homeostasis. There have been contradictory reports of the 
activity of the RAAS in diabetes mellitus. Some workers have 
found activity to be normal [Feldt-Rasmussen et al 1987, 
O'Hare et al 1988], while others have found it to be increased 
[De Chatel et al 1977] or decreased [Christlieb et al 1976, 
Tuck et al 1979]. Leutscher and Kraemer [1988] reported 
recently that patients with microproteinuria have increased 
levels of circulating prorenin. In a prospective study of 
teenage diabetics 34% of those who had elevated rates of 
albumin excretion at re-examination after five years tended to 
have significantly increased plasma renin activity [Paulsen et 
al 1989]. These workers hypothesise that elevated angiotensin 
II levels associated with high plasma renin activity may 
increase glomerular capillary pressure and provoke proteinuria 
and glomerular damage. 
1 .4 .5 .  Glomerular Hypertension 
Glomerular hyperfiltration appears to be a risk factor 
for the development of diabetic nephropathy [Hostetter et 
al 1982, Zatz et al 1986]. Diabetic patients with persistent 
hyperfiltration are more likely to progress to persistent 
Proteinuria than patients with lower initial glomerular 
filtration rates [Mogensen and Christensen 1984a]. The 
amount of any substance filtered from the plasma at the 
glomerulus depends not only in the intrinsic permeability of 
the glomerular basement membrane which, in turn, is determined 
by the pore size and the electrical charge, but also on the 
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amount of blood passing through the capillaries in a unit time 
[perfusion] and the intracapillary pressure [Figure 1-1]. 
Animal data have suggested that single-nephron hyperfiltration 
is dependent on both glomerular capillary hyperperfusion and 
hypertension [Hostetter et al 1981]. Measures which increase 
glomerular capillary perfusion in the remaining nephropans, 
such as partial or unilateral nephrectomy, accelerate the 
development of diabeteic nephropathy [Steffes et al 1978, 
O'Donnell et al 1986]. Zatz and co-workers [1986] treated 
diabetic rats with enalapril, an angiotensin conveting enzyme 
[ACE] inhibitor. A dose which lowered the systemic blood 
pressure in these normotensive animals also reduced their 
glomerular capillary pressure and transglomerular capillary 
pressure gradient. Treated animals did not develop proteinuria 
or histological evidence of diabetic nephropathy whereas 
untreated control animals did. Both groups had comparable 
elevations of blood glucose, thus supporting the hypothesis 
that glomerular hypertension, rather than metabolic 
abnormalities, is of major importance in the evolution of 
diabetic nephropathy [Zatz et al 1986,1987]. 
A recent study of renal function in diabetic 
children, however, does not support the animal data [Drummond 
et al 1989]. This was a double-blind randomized crossover 
trial comparing enalapril with placebo in diabetic children 
with raised glomerular filtration rates, but normal blood 
Pressure and albumin excretion rates. During enalapril 
treatment there was a significant reduction in systemic blood 
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FIGURE 1.1. 
Hypothetical role of glomerular hyperfiltration in the 
initiation and progression of diabetic nephropathy. 
Hyperfiltration is stimulated by extracellular fluid volume 
[ECFV] expansion, renal hypertrophy, and vasoactive hormones. 
increased glomerular transcapillary pressure [dP] and 
glomerular plasma flow rate [Qa] are responsible for 
hyperfiltration leading to albuminuria, mesangial deposition 
of circulating proteins and glomerulosclerosis. [SNGFR = 
single nephron glomerular filtration rate]. 
pressure but no change in glomerular filtration rate, renal 
plasma flow or filtration fraction. The authors concluded 
that the renin-angiotensin-aldosterone system plays no role in 
the hyperfiltration of diabetes, and inferred that there is no 
evidence of glomerular hypertension in this group of patients. 
In the absence of glomerular micropuncture studies it is not 
possible to be dogmatic on this point. Elevation of glomerular 
filtration rate is common early in diabetes but not all 
patients progress to nephropathy. Glomerular hypertension may 
be an important factor in the initiation of nephropathy in 
susceptible patients later in the course of their disease. 
1.4.6. Renal Prostaglandins 
The kidney is one of the most active prostaglandin 
producing tissues. The glomeruli synthesise mainly a 
vasodilator, [determined as its metabolite but 
also some thromboxane and and 
Ardaillou 1986]. Prostaglandins play a contributory role in 
renal autoregulation [Schnerman et al 1984]. They may 
influence glomerular filtration rate by altering efferent and 
afferent arteriolar tone [Schor et al 1981, Schnerman et al 
1984], by influencing the renin-angiotensin-aldosterone 
system [Schor et al 1981], and by effecting mesangial 
Contraction [Scharschmidt et al 1983]. 
Esmatjes et al [1985] studied 21 type 1 diabetic 
Patients and 15 non-diabetic control subjects. Di abet i c 
Patients had increased glomerular filtration rate and renal 
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plasma flow but urinary excretion of and 
was no different from control subjects'. Administration of 
lysine acetylsalicylate, a cyclo-oxygenase inhibitor, 
significantly reduced glomerular filtration rate and renal 
plasma flow in the diabetic group only suggesting that renal 
prostaglandins are involved in the hyperfiltration of type 1 
diabetes. In a similar study using a different cyclo- 
oxygenase inhibitor, piroxicam, there were similar reductions 
in glomerular filtration rate and urinary prostaglandin 
excretion during treatment [Gambardella et al 1988]. 
Barnett et al [1987] compared glomerular and mesangial 
prostaglandin synthesis and glomerular contraction in two 
rat models of diabetes. They found that even though 
streptozocin rats had enhanced production in vivo the 
contractile response of isolated glomeruli to different 
pressors was the same in each group. This argues against 
prostaglandins being important for hyperfiltration in 
diabetes. Jenkins et al [1989] found that indomethacin 
reduced urinary excretion of and without 
altering renal blood flow or glomerular filtration rate. 
Studies of the effects of prostaglandin inhibition in 
diabetic nephropathy suggest that prostaglandins are 
import ant influences upon renal haemodynamics and 
proteinuria. Hommel et al [1987] treated nephropathic type 1 
diabetic patients with indomethacin and found reductions in 
urinary excretion of and albumin and of glomerular 
filtration rate. In a similar study of type 1 diabetic 
18 
patients with incipient nephropathy there were reductions in 
albuminuria but no change in glomerular filtration 
rate [Mathiesen et al 1988]. Barnett et al [1984] have 
reported reduction in diabetic albuminuria in patients 
treated with a specific thromboxane synthetase inhibitor. 
1.5. Modifying the Course of Diabetic Nephropathy 
From the above it may be seen that the most useful was 
in which to affect the course of diabetic nephropathy is by 
adjustment of blood pressure. 
1.5.1. Hypertension in Overt Diabetic Nephropathy. 
Systemic hypertension is associated with diabetic 
nephropathy and plays a role in its development [Parving et al 
1983a]. Those patients with persistent hypertension have a 
faster decline in renal function than those without 
[Hasslacher et al 1985]. 
Several studies have shown that treatment of 
hypertension in overt diabetic nephropathy may retard, but 
not halt, the inevitable decline into end-stage renal 
failure. The first of these w a s  reported by Mogensen [1976]. 
This study involved 8 patients with persistent proteinuria in 
the range 0.5 to 8.8 g 24 and mean systemic blood 
Pressure 161/101 mm Hg. These patients were examined 
between two and four times over a six to sixty month period. 
Treatment commenced with propranolol or combined with 
hydralazine and frusemide. During the 47 day treatment 
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period albumin 
excretion rate was significantly reduced from a mean of 3547 
to 2412 It is unclear in this report 
whether all patients had type 1 diabetes mellitus. 
mean blood pressure fell to 143/93 mm Hg and 
In an extended follow-up study by the same worker six 
men with type 1 diabetes were followed for a mean of 73 months 
[Mogensen 1982]. During the 28 month control period before 
active treatment the mean glomerular filtration rate was 86.1 
ml and the mean monthly decline was 1.23 ml 
During treatment of hypertension the decline in glomerular 
filtration rate was 0.49 ml and the mean blood pressure 
fell from 162/103 mm Hg to 144/95 mm Hg. There was a 
corresponding fall in the mean yearly increase of albumin 
excretion [expressed as a percentage of glomerular filtration 
rate] from 107% during the control period to only 5% during 
active treatment. 
A similar study following ten diabetic patients with 
persistent proteinuria for 29 months before and 39 months 
after treatment with metoprolol, hydralazine and frusemide or 
thiazide reported a fall in mean blood pressure from 144/97 mm 
Hg to 128/84 mm Hg, and a fall of albumin excretion from 977 
to 433 [Parving et al 1983b]. The rate of 
decline of glomerular filtration rate fell from 0.91 mi 
before treatment to 0.39 ml during 
treatment. 
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The results of a long term follow-up study of the 
treatment of hypertension in patients with persistent 
proteinuira has been published recently [Parving and Hommel 
1989a]. Forty-five patients were followed until death or for 
at least ten years following the onset of persistent 
proteinuria. Forty-one patients received treatment for 
hypertension, 19 of whom were receiving triple therapy. The 
mean blood pressure et the onset of treatment was 148/95 mm 
Hg Systolic blood pressure was virtually unchanged whereas 
diastolic blood pressure fell by 0.87 mm Hg per year during 
treatment. The cumulative death rate was 18% at ten years 
after the onset of nephropathy and the overall mortality was 
31%. These results are in marked contrast to previous 
reports of death rates [between 50 and 77%] at ten years after 
the onset of nephropathy [Andersen et al 1983, Krolewski et al 
1985]. The authors attribute this improvement in mortality to 
closer attention to blood pressure control in the study group 
over the previous decade. 
1.5.2. Hypertension in Incipient Diabetic Nephropathy. 
Interest has focussed recently on the possibilty of 
treating patients at an earlier stage of the nephropathic 
Process in an effort to arrest its progress. Inci pi ent 
nephropathy [the phase of microproteinuria] may last 15 years 
or longer before overt nephropathy develops. Although not 
hypertensive by conventional criteria these patients have 
Significantly elevated blood pressure compared with non- 
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diabetic controls [Mathiesen et al 1984, Wiseman et al 1984, 
Christensen et al 1985]. There is also a correlation between 
diastolic blood pressure and albumin excretion rate [Wiseman 
et al 1984]. Most workers have regarded hypertension as an 
important causative factor in the genesis of diabetic 
nephropathy but Mathiesen et al [1990] have published data 
showing a rise in albumin excretion rate preceding sustained 
rises in blood pressure in their patients. 
Because incipient nephropathy may have such a protracted 
course long term studies of blood pressure control have not 
yet been performed. Short term studies, however, have 
yielded promising results. A study of the effect of acute 
reduction in blood pressure, using a stat dose of clonidine 
in patients with incipient nephropathy, produced a reduction 
in systemic blood pressure accompanied by a fall in albumin 
excretion rate [Hommel et al 1986a]. Christensen and 
colleagues [1985] followed six male patients with incipient 
nephropathy fo r  a mean of 5.4 3.0 years before and 4.7 
1 . 0  years after treatment with a combination of ß-blocker and 
diuretic. During treatment there was a significant reduction 
in mean arterial pressure [diastolic + one third of pulse 
Pressure] and an annual decrease of 19 10% in mean albumin 
excretion rate. Prior to the commencement of antihypertensive 
treatment there had been an increase in mean albumin 
excretion rate of 18 17% per year. In this study there 
Was a small, but significant, fall in glomerular filtration 
rate. Although the results of these studies suggest that 
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treatment of blood pressure in incipient nephropathy is 
beneficial they are based on small numbers of patients and of 
relatively short duration. Longer duration studies of 
patients with incipient nephropathy are required to establish 
whether treatment of supranormal or hypertensive blood 
pressure has a place in their management. 
1 .5 .3 .  The Place of Anqiotensin Convertins Enzyme [ACE] 
Inhibitors in the Treatment of Diabetic Nephropathy 
There is at present great interest in the role of ACE 
inhibitors in the treatment of hypertension in patients with 
diabetic nephropathy. ACE inhibitors work by preventing the 
conversion of angiotensin I to angiotensin II. Angiotensin 
II stimulates al dos te secret ion and causes 
vasoconstriction, both of which tend to raise blood pressure. 
ACE inhibitors exert their intra-renal effects predominantly 
at the efferent glomerular arteriole, causing vasorelaxation, 
and thus lowering the intraglomerular capillary pressure [Zatz 
et al 1986, Anderson et al 1986]. As mentioned earlier there 
is evidence that glomerular hypertension is important in the 
pathogenesis of diabetic nephropathy and that its reduction 
Prevents structural injury and proteinuria [Steffes et al 
1978]. Reduction of intraglomerular pressure with ACE 
inhibitors exerts a protective effect in both normotensive-and 
hypertensive diabetic animals [Cooper et al 1989]. In this 
Paper normotensive and spontaneously hypertensive rats were 
rendered diabetic by injection of streptozocin and then 
treated with enalapril or placebo. Both groups of enalapril 
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reated rats showed a reduction in glomerular basement 
membrane thickening, albuminuria and systemic hypertension. 
1.5.3.1. ACE Inhibitors and Overt Diabetic Nephropathy 
ACE inhibitors are efficacious in the treatment of 
systemic hypertension and, along with other antihypertensive 
drugs, reduce protein excretion in diabetic nephropathy. 
Taguma and co-workers [1985] described a reduction of 
proteinuria in patients with overt diabetic nephropathy who 
were treated with captopril. These patients were taking 
other antihypertensive medications which were not altered 
during the study. The mean urinary protein excretion fell 
from 10.6 2.2 g to 6 . 1  1 .4  g after two weeks 
treatment and with no significant fall in systemic blood 
pressure. A succession of papers from workers in Scandinavia 
has shown that ACE inhibitors reduce blood pressure and 
proteinuria in hypertensive diabetic patients with 
nephropathy. 
In his first paper on this subject Björck et al [1986] 
followed 15 patients with diabetic nephropathy treated with 
captopril and found a reduction in mean blood pressure of 5 mm 
Hg and a reduction in the rate of fall of glomerular 
filtration rate from 10.3 ml to 2.4 ml 
There was no correlation between the reduction in 
blood pressure and the reduction in the rate of deterioration 
Of renal function. Neither was there any change in mean 
urinary protein excretion [2.9 2.0 g before and 2.8 
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1.9 g after treatment]. Hommel and co-workers [1986b] 
studied the effect of 12 weeks captopril treatment on 16 
hypertensive patients with diabetic nephropathy. They found 
that blood pressure fell from 147/94 min Hg to 135/88 min Hg, 
and albuminuria from a median of 1549 [range 168-2198] min- 
to li70 frange 352-2238] Parving et al [1988b] 
treated 18 hypertensive nephropaths for about two and a half 
years with captopril and frusemide or bendrofluazide. Mean 
arterial blood pressure fell by 8.7 1.3 min Hg in the treated 
group and rose by 6.6 1.5 mm Hg in a placebo group. Albumin 
excretion fell from 982 to 390 in the 
captopril group and rose from 936 to 1367 
in the placebo group. The rate of decrease of glomerular 
filtration rate was lower in the captopril treated group 5.8 
0.7 ml vs. 10.0 1.3 ml This study, 
however, is open to criticism in that it was non-randomised 
and used historical controls. Björck et al [1990] in a 
prospective, open randomised study comparing enalapril with 
metoprolol in diabetic nephropathy found a greater reduction 
in albuminuria in the enalapril treated group after eight 
weeks. After 2.2 years treatment the rate of reduction in 
glomerular filtration rate was 2.0 3.2 
and in the metoprolol group was 5.6 5.9 
[Björck et al 1992]. 
It has been suggested that ACE inhibitors offer better 
renal protection than other classes of antihypertensive drug. 
This is born out by Björck's data [1990,1992] and by Holdaas's 
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[1991]. Holdaas and colleagues compared the effects of 
lisinopril with those of nifedipine on twelve diabetics in an 
open randomized cross over study. There were four-week wash 
out periods and active treatment periods lasting three weeks. 
Lisinopril reduced albumin excretion from 1343 337 
to 879 299 but nifedipine had no effect 1436 336 
to 1319 342 Neither drug had any effect 
on glomerular filtration rate. 
1.5.3.2. ACE Inhibitors and Incipient Diabetic Nephropathy. 
If observed reductions in rates of decline of renal 
function, and changes in albumin excretion rates, in patients 
with nephropathy are independent of changes in blood pressure 
it supports the view that ACE inhibitors have intrinsic renal 
protective properties. Several recent papers are of interest 
in this respect because they have reported the effects of ACE 
inhibition on renal function in normotensive diabetic 
patients. The earliest of these came from Marre et al 
[1988]. They studied 20 normotensive diabetic patients with 
persistent microalbuminuria for 12 months. Patients were 
randomised to receive either placebo or enalapril and were 
followed double blind for six months and then single blind for 
the remainder of the study. Three placebo treated patients 
developed frank nephropathy whereas none of the enalapril 
treated patients did and five had become normoalbuminuric. 
Mean arterial pressure fell with enalapril but rose with 
placebo. Similarly renal resistance and filtration fraction 
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fell with enalapril suggesting a specific intra-renal effect. 
Parving et al [1989b] reported on normotensive patients with 
AER > 200 min-' who were treated with placebo or captopril 
in an open randomised study. At one year there were 
reductions in mean arterial blood pressure, albuminuria and 
fractional albumin clearance in the treated group and rises in 
the placebo group and the rate of decline of glomerular 
filtration rate was less than in the placebo group. The 
importance of this study is that it has demonstrated that, in 
normotensive patients with overt nephropathy, the increase in 
albumin excretion rate may be not only slowed, but arrested 
completely. Mathiesen et al [1991] reported the four year 
results for  normotensive microalbuminuric patients given 
captopril or placebo in an open randomised study. The trends 
were similar to Parving's study; no captopril treated patient 
had developed nephropathy but seven from the placebo group 
had. Interestingly there was no difference between the groups 
for glomerular filtration rate. 
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CHAPTER 2. 
DIABETIC PROTEINURIA - LITERATURE REVIEW 
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Hippocrates observed more than 2,000  years ago that 
bles on the surface of the urine are a sign of diseases of 
he kidney: we know now that this is a clinical sign of 
roteinuria. It was recognized as early as 1770 that the urine 
f some diabetic patients may contain protein [Cotunnius]. 
Rayer [1840] postulated that diabetes may cause a form of 
Bright's disease. It is now recognized that proteinuria is 
an important marker for the presence of diabetic nephropathy. 
While several proteins may be lost in the urine in diabetic 
nephropathy most workers have concentrated their attention 
upon the behaviour of albumin. In this chapter I will review 
briefly the literature regarding the mechanisms of proteinuria 
in diabetes mellitus and then go on to consider other proteins 
and enzymes which have been investigated and the most suitable 
means of collecting urine specimens for study. 
2.1. Mechanisms of Proteinuria in Diabetes Mellitus. 
The non-diabetic glomerular basement membrane acts as a 
size and charge selective barrier [Dennis and Robinson 
1986]. Evidence for this comes from dextran filtration 
studies in which dextrans of different molecular size have 
been infused and their appearance in the urine studied 
[Brenner et al 1978]. An ideal test macromolecule is 
neither secreted nor reabsorbed and if excretion of the 
reference solute is not altered by tubular function then the 
ratio of urinary clearance of test to reference solute is 
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al to the ratio of the concentration of the test solute in 
Bowman’s space to its concentration in plasma. This ratio 
f clearances is known as the permselectivity and varies from 
where no test molecule appears in the urine, to 1 when 
ere is perfect clearance. It has been shown that neutral 
dextrans with molecular radius < 14A have permselectivity of 
As the radius of the dextran increases towards that of 
albumin [36A] the permselectivity falls [Arturson et al 
1971]. Hence it has been inferred that the glomerular 
basement membrane is size selective. 
Chang et al [1975] studied the effect of charge on 
the seiving of molecules at the glomerular basement membrane 
by comparing permselectivities of neutral dextran and 
[anionic] sulphated dextran. He demonstrated that neutral 
dextrans were size-limited beyond 20A whereas anioinc 
dextrans were restricted over the entire range of molecular 
sizes studied. Since there is no evidence for tubular 
secretion or reabsorption of dextrans the observed 
differences must be a consequence of another process - 
basememt membrane charge. The fact that this is likely to be 
a negative charge is further suggested by enhanced excretion 
Of cationic proteins [Rennke et al 1978]. The glomerular 
basement membrane is composed largely of glycoproteins with 
many carboxyl residues and sulphate rich proteoglycans which 
are both negatively charged [Cotran and Rennke 1983]. 
Glomerular polyanion can be demonstrated histochemically by 
Staining with colloidal iron and Alcian Blue [Michael et al 
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1970]. Simplification of the foot processes of glomerular 
epithelial cells occurs in nephrotic man and animals, 
possibly as a consequence of alteration sin glomerular 
basement membrane charge. This may lead to alterations in 
the size and shape of slit pores and facilitate the passage 
of proteins [Luke 1984]. Similar mechanisms may operate in 
diabetes. 
2.1.1. Glomerular Basement Membrane in Diabetes Mellitus 
Ala-Houhala and Pasternak [1987] studied fractional 
dextran clearances in diabetic nephropathy and concluded that 
altered glomerular permeability was a consequence of 
reductions in charge rather than altered size of the membrane 
pores. Nakamura et al [1988] infused dextrans into patients 
with diabetic nephropathy and found similar results. The 
mechanism of this proteinuria probably relates to alterations 
of glomerular basement charge. Decreased de-novo synthesis of 
glomerular proteoglycans has been demonstrated in diabetic 
rats [Kanwar et al 1983]. A reduction of glycosaminoglycan 
component of the glomerular basement membrane has been 
demonstrated in humans [Partharasarathy et al 1982] and 
altered charge has been reported by Cohen and Surma [1984]. 
2.1.2. Alterations in Serum Proteins 
A further factor of importance in the glomerular 
excretion of protein is the charge of the filtered molecule 
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It is well recognized that glycated proteins 
averse glomerular membrane more easily than native 
glycated proteins [Ghiggeri et al 1984a, Williams and 
iegal 1985, Bertolatus and Hunsicker 1985, Layton and Jerums 
The three dimensional shape of a protein may affect its 
renal handl ing. Enhanced glomerular excretion of dextrans 
may be a consequence of their unfolding from a globular 
structure into a string-like shape [reptation] [Ryan 1981]. 
Ghiggeri et al [1984b] demonstrated urinary excretion of 
albumin with altered three dimensional conformation in 
patients with diabetic nephropathy. Molecular conformation 
may also be important for tubular reabsorption since filtered 
proteins with similar iso-electric points and sizes may be 
taken up at different rates by the tubules [Purtell et al 
1979 ]. 
2.1.3. Altered Renal Tubular Function 
It is thought that nearly all of the albumin filtered at 
the glomerulus is reabsorbed in the healthy renal tubule 
[Galaske et al 1979] by energy dependent endocytosis [Straus 
1964]. The concentration of albumin in glomerular filtrate 
has not been measured directly in the human but Mogensen 
[1977] inhibited tubular reabsorption by infusing lysine and 
reported urinary albumin excretion in the order of 500 mg 
Impaired renal tubular reabsorption could account for 
some part of diabetic proteinuria. Results from different 
studies, however, have been conflicting with some workers 
32 
finding altered, [Abrass 1984, Fletcher et al 1986, Gibb et 
al 1989] and others normal tubular function [Mathiesen et al 
1984] 
2 . 2 .  Proteins and Enzymes other than Albumin 
A range of urinary proteins and enzymes have been 
studied as potential markers for diabetic nephropathy. These 
include those thought to originate or be handled primarily by 
the renal tubules, and 
glucosaminidase [NAG], and the glomerulus, transferrin. 
2.2.1. 
is a low molecular weight protein 
present as part of the histocompatibility antigen on cell 
membranes and is turned over at a constant rate. It is 
readily filtered at the glomerulus and nearly 100% reabsorbed 
in the proximal renal tubule where it is catabolised [Bernier 
1969]. Hence, the protein should be useful as a measure of 
renal function. Walton et al [1988], however, found 
microglobulin excretion to be a poor marker for tubular 
function in diabetic children with microalbuminuria. Viberti 
et al [1981] compared plasma and creatinine 
levels in proteinuric diabetic patients whose renal function 
was assessed by clearance of They found that 
microglobulin levels were elevated in all patients with 
glomerular filtration rate less than 80 ml 1.73 
whereas some patients had normal serum creatinine. This work 
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has been criticised, however, since their range for 
normal levels was based on data from only 12 
patients. has been studied in patients with 
diabetic nephropathy [Jones et al 1980]. It appears that in 
these patients when GFR is normal so too is urinary 
microglobulin excretion. Fletcher et al [1986] studied low 
molecular weight proteinuria by polyacrylamide gel 
electrophoresis [PAGE] in diabetic patients with increased 
albuminuria. They found that no patient had increased 
microglobulin levels. In a study of Albustix negative 
patients glycaemic control appeared to be an important 
modifying influence on excretion [Watanabe 
et al 1987]. excretion may also be 
influenced by exercise [vide inf]. 
2.2.2. N-acetvl-ß-D-qlucosaminidase [NAG] 
Urinary N-acetyl-ß-D-glucosaminidase [NAG] is a 
lysosomal enzyme in the proximal renal tubule [Pugh & Walker 
1960]. It may be elevated in diabetics with and without 
nephropathy [Whiting et al 1979a, 1979b, Cohen et al 1981]. 
Watanabe et al [1987] measured serum and urinary NAG levels 
in 61 diabetic patients who did not have macroalbuminuria and 
19 age and sex matched control subjects. They found that all 
the diabetic subjects, even those with disease duration less 
than 2.5 years, had increased NAG levels. Levels were 
strongly correlated with glycaemic control suggesting that 
they are not particularly useful as a marker of renal 
function in this group of patients. Other workers studying 
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NAG excretion in diabetic patients and non-diabetic control 
subjects found increased levels in all diabetic subjects and 
higher levels in those with proteinuria [Jung et al, 1988]. 
They concluded that NAG may be a useful marker for diabetic 
nephropathy. Type 1 diabetic children without nephropathy 
have increased urinary NAG levels [Gibb et al 1989] and these 
correlate with urinary transferrin but not albumin excretion 
[Martin et al 1990a]. 
2.2.3. Transferrin 
Transferrin is similar in size and molecular weight to 
albumin [38A, 77,000]. Elevated urinary transferrin 
excretion rates have been reported recently in patients with 
complications from type 2 diabetes [Cheung et al 1989]. These 
workers studied 157 type 2 diabetic patients and 53 non 
diabetic control subjects and found significantly higher 
tansferrin excretion in the diabetic group. When the 
diabetic patients were split into three sub groups with 
progressively higher urinary albumin excretion there was also 
progressively higher transferrin excretion which correlated 
with arterial pressure. 
Two groups have suggested that urinary transferrin may 
be an early marker for renal damage in diabetes mellitus. 
Bernard et al [1988] studied transferrin and albumin excretion 
in type 1 [n=84], type 2 [n=23], and type 3 [n=69] diabetic 
subjects. They found increased excretion of both proteins in 
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8 subjects, with increased transferrin alone in 23 and 
increased albumin alone in only 7. There was a better 
correlation between the two proteins for those subjects with 
he highest albumin excretion rates. They were able to 
reproduce these observations in streptozocin diabetic rats. 
The second group of workers [Martin et al, 1988] studied 
patients with either Albustix negative type 1 diabetes 
mellitus [n=54], systemic lupus erythematosus [n=13], 
rheumatoid arthritis [n=17], lymphoma [n=16] or childhood 
nephropathy [n=15]. In all groups there was a relatively 
greater proportional rise in transferrin than albumin 
excretion compared with a healthy control group [n=31]. The 
same group have reported increased urinary transferrin 
excretion in children with type 1 diabetes [Martin et al 
1989]. In a comparison of 74 diabetic children with 40 non 
diabetic control subjects the urinary transferrin excretion 
was significantly elevated and 17 diabetic children had 
excretion rates above the 95th centile. In contrast there 
was no significant increase in albumin excretion in the 
diabetic children. Ellis et al [1983] studied 67 type 1 
diabetic children and found increased transferrin, albumin, 
IgG, and excretion compared with controls. 
These children had normal or increased glomerular filtration 
rates. The observed patterns of proteinuria in this study 
Suggest both glomerular and tubular dysfunction. 
Disproportionate increases of transferrin over albumin 
excretion have been reported previously in a wide range of 
glomerular and tubular diseases [Coimbra et al 1984]. 
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2 . 3 .  Which Urine Sample? 
The traditional clinical definition of 
diabetic nephropathy rests upon the observation of a mean 
urinary protein excretion rate greater than 0 . 5  g in at 
least 3 collections in a patient who has been diabetic for 
more than 10 years [Mogensen 1988a]. Patients with this 
degree of proteinuria are Albustix positive i.e. their 
proteinuria may be detected on simple stick testing of random 
urine samples. This level represents an albumin excretion 
rate of 200 Problems arise in the detection of 
patients with lesser degress of proteinuria. As mentioned 
above [1.2.2. Prevalence of Microproteinuria] different 
workers have used not only different reference values but also 
different time periods for urine collection. Early morning 
urine samples with albumin:creatinine ratio greater than 3.0 
reliably predict an albumin excretion rate greater than 30 
in overnight urine collections [Marshall 1991]. It is 
generally agreed, however, that early morning specimens are 
useful only for screening purposes [Hutchison and Paterson 
1988, Winocour 1992]. Albumin excretion rates demonstrate a 
day to day variability of as much as 37% [Howey et al 1987, 
Cohen et al 1987] and may be affected by many factors, 
especially exercise [Mogensen 1975, 1979; Viberti et al 
1978]. 
Twenty-four hour urine collections are notoriously 
difficult to make accurately. Overnight collections have the 
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advantages that they do not interfere with the patients daily 
routine; they do not necessitate carrying a large collection 
bottle during the day; they are less prone to variability, 
perhaps because they are not subject to the influences of 
exercise which pertain during the day [Chachati et al 1986, 
Cohen et al 1987]. 
2 .4 .  The Influence of Exercise on Diabetic Proteinuria 
As mentioned above albumin excretion may be influenced 
by exercise; indeed, it has been suggested that exercise be 
used as a provocative test to identify patients at risk of 
diabetic renal disease [Feldt-Rasmussen et al 1985]. The 
mechanisms underlying exercise induced proteinuria are 
unknown. Huttunen et al [1981] found increased albumin but 
decreased excretion in exercising non- 
diabetic children and adolescents. Poortmans et al [1988] 
exercised healthy non-diabetic men with and without lysine 
infusion on bicycles. [Lysine is thought to interfere with 
tubular reabsorption of filtered protein]. They found 
increased albumin and excretion after short 
term exhaustive exercise suggesting both increased glomerular 
permeability and reduced tubular reabsorption. Viberti et 
al [1978] used ratios as a measure 
Of proteinuria in exercising diabetic patients and found 
evidence for a glomerular but not tubular leak. Ala Houhala 
[1990] studied fractional protein and dextran clearances in 
12 proteinuric diabetic and 12 non-diabetic subjects at rest 
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and after exercise. Exercise reduced glomerular filtration 
rate and renal blood flow and increased the filtration 
fraction in both groups. In addition there was increased 
clearance of large molecular radius dextran in the diabetic 
group. He concludes that exercise induced proteinuria is a 
consequence of altered renal haemodynamics and increased size 
of the glomerular basement membrane pores. 
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PART I 
URINARY TRANSFERRIN EXCRETION 
IN DIABETIC RENAL DISEASE 
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CHAPTER 3 .  
METHODS 
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3 . 1 .  URINE COLLECTION 
For  screening of the type 1 diabetic patients to 
establish prevalence of proteinuria and during interventional 
studies with angiotensin converting enzyme [ACE] inhibitors 
overnight collections of urine were made. 
Patients were provided with plastic collection 
bottles without preservative. They were instructed to empty 
their bladder prior to retiring for the night and to record 
the time on the bottle's label. They were then instructed 
to collect any urine passed during the night and the first 
urine passed the following morning and to record the time of 
the morning specimen. Samples were returned to the 
hospital on the morning that the collection was completed. 
The total volume and the time of the collection were noted. A 
fresh aliquot was sent to exclude urinary tract infection and 
other aliquots were frozen at -70 for later assay for 
protein content. 
For study of the prevalence of transferrinuria in 
newly diagnosed type 2 diabetic patients and of the effect of 
exercise on transferrinuria in type 1 diabetic patients timed 
urine samples were collected as described later. 
3.2. BLOOD PRESSURE 
Blood pressures were measured at heart level in 
the right arm after at least ten minutes rest using a 
Hawksley random zero sphygmomanometer. Diastolic blood 
pressure was recorded as Korotkow phase V. Mean arterial 
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blood pressure [MAP] was calculated as Diastolic pressure + 
[0.33 x Pulse pressure]. 
3 . 3 .  VENESECTION 
All blood specimens were drawn from an antecubital 
vein without venous stasis after blood pressure had been 
measured. 
3.4. SERUM ELECTROLYTES AND ALBUMIN 
Serum sodium, potassium, urea, creatinine, and 
albumin were measured using a Vickers SB-120 multi-channel 
autoanalyser. 
3.5. GLUCOSE and GLYCATED HAEMOGLOBIN 
Glucose was measured using a glucose oxidase 
method (Trinder 1969], glycated haemoglobin by 
affinity chromatography using Glycogel-B [Mallia et al 1981]. 
3.6. PLASMA RENIN ACTIVITY 
This was measured using an endogenous Substrate 
assay. Four plasma sample [0.2 ml] from each patients were 
incubated at 37 with 0.2 ml of 0.2 mol sodium 
phosphate buffer [pH 6.0] containing the following 
angiotensin converting enzyme and angiotensinase inhibitors; 
3.0 mmol EDTA [Ethylene diamine tetra-acetic acid], 8.5 
mmol and 5.0 mmol dimercaprol. 
Incubations were stopped at O, 15, 45, and 180 min by 
plunging the incubation tubes into liquid nitrogen.The amount 
of angiotensin I produced from endogenous angiotensin was 
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determined by an in-house technique using 
radiolabelled I prepared by the chloramine T 
method. Samples of the enzyme incubations were added 
to tubes containing buffer 
containing g human serum albumin and 2 g 
neomycin sulphate; 0.2 of angiotensin I antiserum 
diluted in buffer 
before use; 0.05 of I [diluted in 
buffer before use]. At the same time angiotensin I 
standards between 156-5000 were est up. The 
was performed by incubating for 72 h at 4 
and stopped by adding 0.05 mol buffer 
containing 10% human plasma and 10 g activated 
charcoal Hopkins and Williams, Heath, 
at 4 After centrifugation at for min the 
radioactivity of the pellet was counted and the angiotensin I 
in each assay tube calculated. The plasma activities 
were then determined employing linear regression on O, 15, 
and 180 min angiotensin I concentrations. Enzyme 
activities were given in angiotensin I produced litre 
asma- at 37 The reference range was 
determined from healthy recumbent adults and was 
Three controls [low, medium, and high} were 
included with each batch, and were 8.3, 7.1, 
7.3 for plasma renin activities of 1.2, 4 . 2 ,  and 15.0 
respectively. 
PLASMA ALDOSTERONE 
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Plasma aldosterone concentrations were determined 
in duplicate by a kit 'Coat-a Count' 
[Diagnostics Products Los Angeles, USA]. Quoted 
reference values for healthy recumbent adults were 
Three control samples were assayed with each 
batch of samples, and the calculated inter batch were 
and for plasma aldosterone concentrations 
of and respectively. 
ATRIAL FACTOR 
This was measured using a two-site 
assay according to the method of Lewis et 
al 
ADRENALINE, NOR-ADRENALINE, AND DOPAMINE 
These were measured by high performance liquid 
chromatography with detection using the 
method described by et al 
URINARY 
Antiserum to human serum [Sigma, 
Poole, was produced in rabbits following subcutaneous 
multisite injection of label 
was prepared by the liquid phase method 
and purified on a column 
Uppsala, Sweden]. Rabbit antiserum to human serum 
was diluted fold in assay buffer [phophate 
buffer 7.5, with bovine serum albumin] 
Containing rabbit carrier serum against 
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precipitating antibody The diluted antiserum 
pi] was incubated at with of human serum 
standard or unknown and tracer 
solution for Sheep antiserum of to 
rabbit Poole, [raised by subcutaneous 
multisite injection of in horse 
buffer was then added to each sample 
followed by of g 
incubated at for min, 
centrifuged and the precipitate counted. Urine specimens 
were diluted fold in assay buffer initially and further 
diluted where appropriate. Recovery was [range 
Cross reactivity of the antibody with albumin was 
at of albumin. The range of the assay was 
Interassay coefficients of variation were: 
at at at 
URINARY ALBUMIN 
Albumin content of urine was measured using a 
double antibody employing radiolabelled 
albumin prepared by a chloramine T method. Assays were 
conducted in duplicate after albumin standards 
stored at and specimens in with 
mol phosphate buffer containing 
sodium chloride, sodium and 
volume inactivated rabbit serum. This buffer was also 
used to make any other dilutions. To each tube was added 
of diluted standard or specimen, of a 
dilution of and 0.2 of a dilution of 
albumin antisera [Atlantic Antibodies, Scarborough, ME 04074, 
USAI. Tubes were vortex mixed and incubated at 37 for 
150 min after which time 0.1 of Sac-cel 
[Immunodiagnostics Systems, Washington, UK] was added. After 
a further 30 min at room temperature 1 of water was added 
to each tube and the tubes were centrifuged at 3000g for 15 
min. After aspiration the radioactivity was counted in the 
cellulose pellets and the concentration of albumin was 
calculated from the generated standard curve. Interbatch CV 
was 7.0, 4.3, and 4.2 for urine concentrations of 10, 44, 
and 161 respectively. 
3.12. MARKERS OF RENAL TUBULAR FUNCTION 
[NAG] was measured by 
spectrofluorimetry as described by Leback and Walker 
was measured by radial immunodiffusion 
using the method of Mancini et al 
3.13. URINARY PROSTAGLANDINS 
and were measured 
in urine using commercially available kits 
employing a double antibody radioimmunoassay. all specimens 
were assayed in duplicate. 
3.14. GLOMERULAR FILTRATION RATE 
This was measured as follows: 
3.14.1. Preparation of Dose and Standard 
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1. 10 ml 10% dextrose was aseptically dispensed into a 
sterile 20 ml vial. 
2. The required volume [3 MBq] of EDTA was dispensed 
into a 1 ml syringe and diluted to 1 ml with sterile water. 
3 .  The EDTA/water was added to the dextrose and volume 
made up to 12 ml using sterile water. 
4. 10 ml of this solution was withdrawn and used for the 
patient dose. This syringe was weighed and before and 
after filling with the patient dose and the weights noted. 
5. 1 ml of the remaining solution was dipensed into a 500 ml 
volumetric flask and made up to 250 ml using sterile water. 
6. Dose and standard were calibrated by weighing 
accurately two syringes each fitted with needle and 
guard before and after drawing up required volumes of 
radio pharmaceutical. The net weights of dose and 
standard were calculated and the ratio of dose:standard was 
derived. 
3.14.2. Technique 
1. A 10 ml heparinized blood sample was taken from the 
patient for count of background activity. 
2. The patient was injected via an antecubital vein and 
the time noted. 
3. Four 10 ml heparinized blood samples were taken at 90, 
150, 210 and 270 min post injection from a site different 
from that used for injection. 
4 .  The blood samples were centrifuged and, from each, 2 ml 
plasma was dispensed into sample tubes. 2ml was dispensed 
from the standard flask into a further sample tube. 
5. The samples were counted along with the standard and 
room background for the same time. All plasma counts and 
standard counts were corrected for background activity. All 
samples were counted in duplicate. 
6 .  Using log-linear graph paper the plasma count was 
plotted [log scale] against time. Using the best straight 
line fit the intercept at time zero [time of injection] and 
half time of clearance in minutes were determined. 
7. The volume of dilution [V] and glomerular filtration 
rate [GFR] were calculated from the following formulae; 
V [litres] = [standard counts] x [dose/standard ratio] 
Intercept 
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GFR [ml = V x 0.693 x 1000 
3.15. EFFECTIVE RENAL PLASMA FLOW 
3.15.1. Preparation of Dose and Standards 
These were prepared in the same manner as those for 
glomerular filtration rate but using a dose of 2 MBq 
hippuran. 
3.15.2. Technique 
The technique was the same as for measurement of glomerular 
filtration rate except that a single blood sample was taken 
44 min after injection. samples were counted as above and 
the volume of distribution [V'] and effective renal plasma 
flow [ERPF] calculated as follows: 
V' [litres] = [standard counts1 x [dose/standard ratio] 
[44min plasma counts] 
ERPF [ml = 5.5 x V' 
3.16. CORRECTION FOR SURFACE AREA 
To correct for differences in body size glomerular filtration 
rate and effective renal plasma flow were corrected for 'a 
body surface area of 1.73 with a nomogram derived from the 
formula of Dubois and Dubois [1916] using weight and height. 
3.17. DERIVED MEASURES 
Filtration Fraction [FF] GFR / ERPF 
Renal resistance [RR] MAP / ERPF 
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Fractional albumin 
Albumin clearance / GFR clearance [FALB] 
3.18. STATISTICAL METHODS 
For  all studies data were found to be non- 
parametrically distributed. For  multiple group comparisons 
the Kruskal Wallis test was used and if this demonstrated a 
difference groups were compared using the Mann Whitney U 
test. Correlations were established with the Spearman Rank 
Order test. These calculations were performed on a PC using 
the Microstat statistical package. For  the two studies 
involving ACE inhibitors analyses were performed on an IBM 
mainframe computer using the SAS statistical package. 
3.18.1. ACE inhibitor in Overt Nephropathy 
For blood pressures, GFR, RBF, ERPF, FF, and 
RR changes from baseline [visit 7 minus visit 2] were 
analysed using the analysis of covariance [ANCOVA] technique: 
the baseline [visit 2] values were further included in the 
model as the covariate as this was found to substantially 
contribute to the models and hence improve the precision of 
the estimates of treatment difference. The assumptions 
underlying the ANCOVA technique were checked against these 
data and were not found to be violated. For AER and 
Quantitative protein, however, the changes from baseline were 
found to violate the normality assumption underlying the 
ANCOVA technique as they were heavily skewed with extreme 
outliners even after logarithmic transformation. Therefore 
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the non parametric Mann Whitney U test was applied to the 
untransformed changes from baseline for these endpoints. 
3.18.2. ACE inhibitor in Incipient Nephropathy 
Primary end points for the study were changes in 
AER, urinary prostaglandins, GFR and RBF after 48 weeks 
treatment. Secondary end points were changes in heart rate, 
blood pressure and metabolic control. Changes from baseline 
[visit 2] to the end of randomised treatment [visit 7] were 
analysed using the analysis of covariance [ANCOVA] technique. 
The baseline values were further included in the model since 
this was found to contribute substantially to the model and 
hence improve the precision of the estimate of treatment 
difference. The assumptions underlying the ANCOVA technique 
[normality and homoscedasticity] were checked against the 
data and found not to be violated. Patients whose 
compliance was less than 80% were excluded from the final 
analyses. 
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CHAPTER 4. 
SCREENING OF CLINIC POPULATION 
AND IDENTIFICATION OF PATIENTS WITH PROTEINURIA 
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4.1. PATIENT SCREENING 
All patients involved in the studies which 
comprise this thesis were recruited from the diabetic clinic 
at East Birmingham Hospital. The clinic has approximately 
3,000 patients with type 1 [insulin dependent] or type 2 
[non-insulin dependent] diabetes mellitus and those with type 
1 diabetes are reviewed at four month intervals. Hence, all 
patients with type 1 diabetes should pass through the clinic 
in a twelve month period. 
For the twelve month period beginning 31st May 
1987 all type 1 diabetics attending the clinic were invited 
to participate in a study to ascertain the prevalence of 
albuminuria. Type 1 diabetic patients were defined as those 
who were diagnosed prior to the age of 35 years, who had at 
least one episode of ketosis, and showed an absolute 
requirement for insulin therapy. Since this is an NHS 
clinic with large numbers of patients it was felt justified 
to make the diagnosis on these clinical grounds. C-Peptide 
levels were not measured as a routine. 
The aims of the study were explained to the 
patients. A full medical history was taken and all patients 
were examined to establish the presence or absence of any 
complications of diabetes or the presence of any other 
disease. Retinopathy was assessed by direct ophthalmoscopy; 
neuropathy by clinical assessment of vibration sense, light 
touch and reflexes; peripheral vascular disease from history 
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and the presence or absence of peripheral pulses 
[brachial:ankle pressures were not measured]: coronary artery 
disease from history and resting electrocardiogram [ECG]. 
Blood pressure was measured twice in the right arm after at 
least ten minutes rest using a Hawksley random zero 
sphygmomanometer. The mean of these readings was recorded. 
Autonomic nervous function was assessed using the battery of 
tests as decribed by Ewing and Clark [1982]. Briefly, this 
involves recording the ECG during slow maximal respiration, 
during the Valsalva manouevre while the patient maintains a 
pressure of 40 mm Hg for 30 seconds, and during the change 
from supine to upright posture. In addition the blood 
pressure response to sustained hand grip is measured and any 
postural drop in blood pressure is recorded. By measuring 
alterations in blood pressure and the maximal and minimal RR 
intervals on the ECG during the different phases of 
respiration and comparing these with standard ratios it is 
possible to establish whether autonomic neuropathy is 
present. 
In addition to routine bloods taken in clinic for 
the management of diabetes a sample was taken from all 
patients for measurement of serum creatinine. 
Patients were instructed how to perform an 
overnight collection of urine and provided with a collection 
bottle and printed instructions to reinforce what had been 
said in clinic. They were asked to return the urine 
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collection to the hospital the morning of its completion. Two 
collections were made within a six month period. On return 
to the hospital the urines were aliquotted; a fresh aliquot 
was sent to exclude urinary tract infection; the remainder 
were frozen at -70 °C pending assay, by radio-immunoassay 
[RIA] ,  for albumin and transferrin. the volume and times of 
collection were recorded for later calculation of protein 
excretion rates. These were calculated from the formula 
PER = Pc x V 
T 
where PER is protein excretion rate, Pc is protein 
concentration in urine, V is volume of urine, and T is time 
of collection of urine. Conventionally the excretion rates 
are expressed as 
4.2. RESULTS 
One hundred and eight patients fulfilling the criteria 
for diagnosis of type 1 diabetes participated in the study. 
Patient characteristics are shown in table 4.1. The median 
[range] age was 27 [12-68] years and disease duration 12 [i- 
49] years. The patients were sub-divided on the basis of 
albumin excretion rate [AER] into normoalbuminuric [AER < 20 
n = 79], microalbuminuric [20 < AER < 200 
n = and macroalbuminuric [AER > 200 19], 
n = 10]. Those with macroalbuminuria had longer 
median[range] disease duration than the other groups [34[20- 
68] years vs 26[15-65] years normo- and 29[12-60]years 
microalbuminuric, P < 0.05]. Forty patients had retinopathy 
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of some degree and this was significantly more common in 
those with elevated AER [19 normo-, 12 micro- and 9 
macroalbuminuric, P < 0.01]. Autonomic and peripheral 
neuropathy, as well as systolic hypertension were more common 
in patients with macroalbuminuria than either of the other 
groups. More patients in the macroalbuminuric group were 
treated for hypertension [9 compared with 6 normo-, and 3 
microalbuminuric, P < 0.01]. Macroalbuminuric patients had 
higher serum creatinine than the other groups [median[ range] 
111[86-215] vs 89[52-126] normo- and 84[66- 
133] microalbuminuric, P < 0.01]. One patient in 
the macroalbuminuric group with peripheral vascular disease 
had had a lower limb amputation. There was no significant 
difference between groups for any other variable, including 
the number who were smokers. 
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4 . 3 .  DISCUSSION 
4.3.1. Prevalence of proteinuria 
Diabetes mellitus is a common disease affecting 
approximately 1.0 % of the population in the United Kingdom. 
It has been reported that as many as 40% of type 1 [insulin 
dependent] diabetic patients may develop nephropathy as a 
disease complication [Andersen 1983]. Other authors, 
however, report a reduction in the incidence of nephropathy 
[Krolewski 1985, Kofoed-Enevoldsen 1987]. These workers 
examined cohorts of type 1 diabetic patients diagnosed in 
different decades and found that those diagnosed later had a 
lower incidence of nephropathy independent of duration of 
diabetes. The reasons for this are unclear; male sex, and 
high body mass index, in addition to year of diagnosis were 
found to be risk factors; social class, insulin dose, place 
of abode, and readmission to a teaching centre did not 
influence the incidence of nephropathy. Smoking habit does 
not appear to have had a major part to play in the 
development of nephropathy since there was an increased 
number of women smokers in later years but still a male 
preponderance of patients with nephropathy. There was, 
however, no account of total amount of tobacco smoked. A 
possible factor in the decreased incidence of nephropathy is 
the treatment of hypertension. 
The high relative mortality of patients with type 
1 diabetes is restricted mainly to those with proteinuria 
[Andersen 1983, Borch-Johnsen 1985]. A decrease in the 
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relative mortality of patients with type 1 diabetes has been 
reported from Denmark although the reason for this was 
unrecognized [Green 1985]. Parving and Hommel [1989a] have 
recently published data showing improved prognosis in 
diabetic nephropathy which they attribute to better treatment 
of hypertension in this group of patients. This study, 
however, may be criticised because of the relatively small 
number of patients [45], the fact that it used historical 
controls, an absence of data regarding duration of diabetes 
in the study group compared with controls, and the effects of 
insulin dosage and glycaemic control. Allowing for these 
criticisms, however, there was a greatly decreased cumulative 
mortality ten years after the onset of nephropathy. 
4.3.2. Prevalence of Microproteinuria 
In the population studied fo r  this thesis nineteen 
[17.6%] patients had microalbuminuria. This figure is in 
broad agreement with the prevalence quoted by Berglund 
[1987] but lower than the figures from other workers 
[Mathiesen 1986, Niazy 1987, Parving 1988a]. As mentioned 
earlier the difference in observed prevalences may relate to 
different definitions of microalbuminuria chosen by different 
groups of researchers. I chose the range 20-200 
since this is now commonly accepted as a working definition. 
4.3.3. Prevalence of Macroproteinuria 
Ten [9.3%] patients had macroalbuminuria. All of 
these had disease duration of at least 10 years and 9 were 
58 
treated for hypertension. Hence, it appears that all had 
developed frank nephropathy. A prevalence of nearly 10% is 
higher than those reported by Daggett [1986], 2.7%, and 
Gatling [1988], 6.8%. Both of their studies, however, were 
of larger groups of unselected [type 1 and type 2] diabetic 
patients. It is possible that my study population has an 
artificially high prevalence because of a sampling error. 
Conversly, it is possible that Daggett's and Gatling's 
figures would be higher if they had examined only type 1 
diabetic patients. 
4 . 3 . 4 .  Prevalence of Retinopathy 
Retinopathy became progressively more prevalent 
with increasing proteinuria in the present study [24% normo-, 
63% micro-, and 90% macroalbuminuric patients]. These figures 
are similar to those reported in previous studies by other 
workers. A n  association between diabetic retinopathy and 
nephropathy is widely accepted; the interaction between 
nephropathy and retinopathy has been termed the diabetic 
renal-retinal syndrome [Friedman 1980]. Severe retinopathy 
is more likely to be found in patients with renal disease 
[Klein 1988] and diabetic retinopathy is more advanced in 
patients with microalbuminuria than those with normal albumin 
excretion rates [Barnett 1985]. Proliferative retinopathy 
also becomes more frequent with increasing albuminuria, being 
found in 28% of patients with microalbuminuria and 58% of 
those with macroalbuminuria in one study [Parving 1988a]. 
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When end-stage diabetic nephropathy is present 70% of 
patients will have proliferative retinopathy and the 
remaining 30% have non-proliferative disease [Ramsay 1979]. 
None of the patients in the present study had such advanced 
disease. 
4.3.5. Nephropathy and Cigarette Smoking 
An association between cigarette smoking and 
nephropathy has been claimed by some authors [Telmer 1984, 
Norden 1984]. I found no difference between groups for the 
number of patients who were current cigarette smokers. In a 
case control study of 192 cigarette smoking patients with 
type 1 diabetes and 192 non smokers there was significantly 
more macroproteinuria [19.3% vs 8.3%, P <0.001] and 
proliferative retinopathy [12.5% vs 6.8%, P <0.025] in the 
smoking group [Mühlhauser et al 1986]. My study and that of 
Mühlhauser looked at crude indices of smoking habit: Stegmayr 
[1987] has suggested that 'pack years' i.e. total amount of 
tobacco smoked is a more appropriate measure of risk. [ A  
person smoking ten cigarettes per day for 4 years would 
accumulate two pack years, etc.] This difference in method 
of calculation of tobacco habit may explain the lack of an 
observed association between smoking and nephropathy in the 
present study. 
In summary,it appears that the population of type 
1 diabetics in the present study are typical in terms of the 
numbers with micro- and macroalbuminuria and the numbers with 
retinopathy. There does appear to be an increased 
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prevalence of retinopathy with increasing albuminuria and, 
similarly, an increased prevalence of hypertension. I could 
not confirm previous workers' reports of an association 
between cigarette smoking and diabetic nephropathy; this may 
relate to the crude method chosen to measure- smoking habit. 
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CHAPTER 5 
URINARY TRANSFERRIN EXCRETION IN TYPE 1 
[INSULIN DEPENDENT] DIABETES MELLITUS. 
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5.1. INTRODUCTION. 
As mentioned above some workers have reported 
a prevalence of 40% for nephropathy in type 1 [insulin 
dependent] diabetic patients [Andersen et al 1983, Krolewski 
et al 1985. Prevalence figures from my study were slightly 
lower [Chapter 4]. Frank nephropathy is preceded by 
consistently elevated urinary albumin excretion rates 
[Viberti et al 1981, Wartha et al 1984, Fletcher et al 1986, 
Jung et al 1988] which do not occur until diabetes has been 
present for several years [Mogensen 1984, Viberti et al 
1982]. Elevated urinary transferrin and N-acetyl-ß-D- 
glucosaminidase excretion rates may precede elevationm of 
albumin excretion rate in diabetic children [Ellis et al 
1983, Martin et al 1990] and may be earlier predictors of 
renal disease. I studied urinary transferrin and albumin 
excretion in adult [type 1] diabetic patients to investigate 
this possibility. 
5.2. SUBJECTS, MATERIALS AND METHODS. 
Subjects were 47 type 1 [insulin dependent] 
diabetic patients who had participated in the initial 
screening of the clinic. Since proteinuira in type 1 
diabetes is uncommon until diabetes has been present for 
several years only patients with disease duration of at least 
5 years were studied. Twenty eight healthy medical and 
laboratory personnel with no family history of diabetes were 
studied as sex-matched controls. 
All subjects were examined as described previously 
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for evidence of large vessel disease or retinopathy. Patients 
were grouped according to albumin excretion rate [AER] 
derived from overnight urine collections [normo- <20 min' 
micro- 20-200 and macroalbuminuric > 200 min- 
=].  Subjects' characteristics and biochemistry results are 
shown in Table 5.1. 
Although macroalbuminuric patients tended to be 
older and to have had diabetes for longer the difference 
between these and other groups was not significant. All 
macroalbuminuric patients were treated for hypertension but 
no other patient or control subject was. There was no 
significant difference in plasma biochemistry or glycaemic 
control between patients with and without elevated 
transferrin excretion rate. There was no significant 
difference in age or sex ratio between diabetic and control 
subjects. 
On the morning of the test, having eaten their 
usual breakfast, all subjects voided urine and were given 
200ml water to drink per hour. After a 1h rest period a 2h 
timed recumbent urine collection was made. Aliquots of urine 
were stored at -20 °C for quantification of albumin, 
transferrin, N-acetyl-ß-D-glucosaminidase [NAG], creatinine, 
and electrolytes. A sample of fresh urine was sent for 
bacteriological examination. Blood was drawn from an 
antecubital vein after the rest period for estimation of 
plasma glucose, glycated haemoglobin creatinine, and 
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albumin. Serum was frozen and stored at -70 °C for 
measurement of transferrin. 
5 . 3 .  RESULTS 
One patient had an asymptomatic urinary tract 
infection and was excluded from further analyses. 
Control urinary transferrin excretion rates [TER] 
ranged from 0.01 to 0.28 (median 0 . 0 4  but 
were skewed by the highest value. The median transferrin 
excretion rate was significantly higher in the diabetic than 
the control group [0.58 vs. 0.04 P <0.001]. Forty 
[85%] diabetic patients had transferrin excretion rates above 
the 95th centile [O.11ug for the range derived from 
the control group. There was no significant difference in 
age, duration of diabetes, or glycaemic control between these 
patients and those with transferrin excretion rates below the 
95th centile value. There were significant differences 
between median transferrin excretion rates of the normo-, 
micro-, and macroalbuminuric groups [0.2, 3.38, and 34.7 
respectively, P <0.001, Table 5.2]. 
Transferrin excretion rates and urinary 
transferrin/creatinine ratios were significantly correlated 
in the diabetic patients [r=0.95, p <0.02]. There were 
significant differences in urinary transferrin/creatinine 
ratios between the diabetic groups and between diabetic and 
control groups [Table 5.2]. Transferrin excretion rate did 
not correlate with age, disease duration or metabolic 
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control or plasma glucose during testing] in any group. 
There was a correlation between albumin and 
transferrin excretion rates in the control [r=0.81, P <0.05] 
and diabetic groups [r=0.78, P <0.001, Fig 5.1]. 
All patients with albuminuria > 20 
had transferrin excretion rates greater than the 95th centile 
value [Fig 5.1]. Twenty-one patients had elevated transferrin 
excretion rates but normal albumin excretion rates. These 
did not differ from other patients with respect to age, 
disease duration or glycaemic control. 
All patients with clinical retinopathy had 
elevated transferrin excretion rates but not all patients 
with elevated transferrin excretion rates had retinopathy 
[Table 5.1]. 
N-acetyl-ß-D-glucosainidase excretion was 
significantly higher in the diabetic than control groups 
[Table 5.3]. There was a correlation between albumin, 
transferrin and N-acetyl-ß-D-glucosainidase excretion rates 
i n  diabetic patients [[Table 5.3]. There was no significant 
correlation between N-acetyl-ß-D-glucosainidase and 
glycaemic control [random plasma glucose or glycated 
haemoglobin]. 
5.4.DISCUSSION 
Elevated urinary transferrin excretion rates 
have been described recently in adults with complications of 
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type 2 diabetes [Cheung et al 1989] and children with type 1 
diabetes [Ellis et al 1983, Martin et al 1990]. A higher 
prevalence of elevated urinary transferrin than albumin 
excretion rates has been reported in a mixed group of type 1 
and type 2 diabetic patients [Bernard et al 1988] and these 
authors suggested that microtransferrinuria may be a more 
sensitive marker of glomerular damage in diabetes than 
microalbuminuria. 
5 . 4 . 1 .  Reference Range for Urinary Transferrin Excretion 
There are few data regarding urinary transferrin 
excretion in health and in particular no data regarding 
normal urinary excretion rates. I studied a group of 28 
non-diabetic subjects to establish a reference range for 
urinary transferrin excretion. All of the control subjects 
were normotensive. They were aged between 21 and 60 years 
[median 31] which is comparable with the age range of 
patients in the present studies. The urinary transferrin 
excretion rates ranged from 0.01 to 0.28 
with a median value 0.04 The values, however, 
were skewed to the lower end of the range and even after 
transformation did not conform to a normal distribution hence 
the 95th centile value [0.11 was taken as the 
upper limit of normal. Urinary transferrin excretion 
increases with age in the rat and is also higher in males 
than females [McCormick et al 1989]. I found no correlation 
between urinary transferrin excretion and age or sex in this 
group of control subjects. 
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5.4.2. Prevalence of transferrinuria 
Most of the [type 1] diabetic subjects [85%] had 
elevated urinary transferrin excretion rates. This 
prevalence is similar to that found in type 2 diabetic 
subjects [Bernard et al 1988]. All of the diabetic subjects 
with albumin excretion rate > 20 had increased 
transferrin excretion rate [ >  0.11 as did all 
patients with retinopathy. However, not all patients with 
increased transferrin excretion rates had evidence of 
complications. This observation offers some support to the 
suggestion that increased urinary transferrin excretion may 
be a marker for the complications of diabetes. 
5.4.3. Mechanism of Transferrinuria 
Possible explanations for elevated transferrin 
excretion rate include: 
5.4.3.1. Altered glomerular capillary basement membrane 
function. 
The normal non-diabetic glomerular capillary 
membrane is both size and charge selective [Dennis and 
Robinson 1986]. Since transferrin is larger than albumin 
[Tietz 1987] difference in size is unlikely to explain 
increased transferrin excretion. In diabetes there may be 
altered glomerular basement membrane charge [Parthasarathy 
and Spiro 1982, Kanwar et al 1983, Cohen and Surma 1984] 
which may facilitate the passage of charged macromolecules. 
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Glycated serum proteins pass more easily across glomerular 
basement membrane [Layton and Jerums 1988, Bertolatus and 
Hunsicker 1985, Williams and Segal 1985, Ghiggeri et al 
1984]. Transferrin, however, is less glycated than albumin in 
diabetes [Austin et al 1987] and so this is an unlikely 
explanation. 
5.4.3.2. Normal slomerular handling of altered serum 
proteins. 
Enhanced glomerular excretion of anionic dextrans 
may be a consequence of unfolding of the normally globular 
structure into a more string-like shape [reptation] [Ryan 
1981]. There are reports of altered three-dimensional 
conformation of albumin in diabetic microproteinuria 
[Ghiggeri 1984]. A similar change in transferrin might favour 
its excretion. There are, however, no data from the present 
studies to confirm or refute this. 
5.4.3.3. Decreased tubular reabsorption of transferrin. 
Tubular function in diabetes has been reported as 
altered [Fletcher et al 1986, Abrass 1984, Gibb et al 1989] 
or normal [Mathiesen et al 1984]. Transferrin [pI 5.8] 
should be preferentially reabsorbed over albumin [pI 4.9] 
[Mathiesen et al 1984, Christensen et al 1983]. Molecular 
conformation is also important, however, since proteins with 
similar sizes and isoelectric points are taken up at 
different rates by renal tubules [Purtell et al 1979]. 
Glycation induced changes in transferrin's structure and/or 
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charge may affect its tubular handling. 
N-acetyl-ß-D-glucosaminidase is a lysosomal enzyme 
originating in the renal tubule [Pugh and Walker 1960] and 
urinary excretion is elevated in various renal disorders 
[Dance and Price 1970, Kunin et al 1978, Whiting et al 1979]. 
Glycaemic control may make a significant contribution to the 
levels of urinary N-acetyl-ß-D-glucosaminidase in diabetes 
mellitus [Watanabe et al 1987]. I found no correlation 
between plasma glucose or glycated haemoglobin and N-acetyl- 
ß-D-glucosaminidase in the patients in this study. There was, 
however, increased urinary excretion of N-acetyl-ß-D- 
glucosaminidase in diabetic subjects compared with non- 
diabetic control subjects. There was higher N-acetyl-ß-D- 
glucosaminidase excretion in patients with greater degrees of 
proteinuria. The correlation between transferrin excretion 
rate and N-acetyl-ß-D-glucosaminidase suggests that there may 
be altered renal tubular handling of this protein. Bernard et 
al [1990] studied urinary transferrin excretion in workers 
exposed to cadmium, a metal known to cause renal tubular 
damage. They found that urinary transferrin excretion rose 
to a greater extent, and at lower blood levels of cadmium, 
than N-acetyl-ß-D-glucosaminidase and other markers of 
tubular function. From these data they suggest that there 
are glomerular basement membrane rather than tubular changes. 
5 . 4 . 3 . 4 .  Increased transferrin Presentins to the glomerulus. 
This is an unlikely explanation since serum levels 
of transferrin were the same in all study groups. 
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It has been suggested that elevated transferrin 
excretion rate may be an early marker of glomerular 
dysfunction [Bernard et al 1988, Martin et al 1988]. The 
data from this cross-sectional study suggest that albumin and 
transferrin are handled differently by the diabetic kidney. 
The majority of patients had elevated transferrin excretion 
rates compared with non-diabetic control subjects. Only 40%, 
however, of type 1 diabetic patients will progress to 
nephropathy. Hence elevated transferrin excretion rate is a 
poor predictor for this complication but may be a marker for 
renal dysfunction. 
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CHAPTER 6 
TRANSFERRINURIA IN TYPE 2 DIABETES: 
EFFECTS OF GLYCAEMIC CONTROL 
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6.1. INTRODUCTION 
Increased levels of albuminuria have been reported 
in newly diagnosed type 1 diabetic patients [Mogensen and 
Schmitz 1988] and these return to normal once diabetes has 
been controlled. Similar findings have been reported in type 
2 diabetes [Martin et al 1990b]. Having observed elevated 
levels of urinary transferrin excretion in adults with type 1 
diabetes and different degrees of albuminuria, and paying 
regard to recent reports of transferrinuria in type 2 
diabetic patients with complications [Cheung et al 1989, 
Bernard et al 1988] it seemed logical to try to answer three 
questions: First, is transferrinuria present at diagnosis in 
type 2 diabetes mellitus? Secondly, how does urinary 
transferrin excretion alter with improved metabolic control? 
Thirdly, does transferrinuria truly relate to the presence of 
diabetic microangiopathy? 
6.2. PATIENTS AND METHODS 
All newly diagnosed type 2 diabetic patients 
without a history of renal disease who attended clinic 
during a six month period were invited to participate. 
Patients who had been prescribed oral hypoglycaemic agents or 
insulin by their general practitioner prior to their first 
clinic attendance were excluded. Patients were studied at 
their initial visit and again after 6 and 12 weeks treatment 
with diet alone or diet and oral hypoglycaemic drugs as 
appropriate. 
Alterations in blood pressure may alter urinary 
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protein excretion. Anti-hypertensive therapy, therefore, was 
not commenced or altered for the duration of the study in any 
i' 
patient. 
At the initial consultation the study aims 
were explained, patients were given a general medical 
examination and evidence of diabetic complications was 
sought. Macrovascular disease was assessed on the basis of 
history, physical examination and resting ECG. Retinopathy 
was assessed by direct ophthalmoscopy and was graded as 
absent, simple [background or pre-proliferative changes] or 
complex [proliferative changes, macular or peri-macular 
exudates]; neuropathy was assessed by clinical tests and was 
graded as present or absent. 
At each visit patients were asked to empty 
their bladders and rest recumbent for 2h having 200 ml water 
per hour to drink. The volume of urine passed during this 
time was recorded and aliquots were frozen at -20 °C for 
later batch analysis of transferrin, albumin, a-1- 
microglobulin [AlM], N-acetyl-ß-D-glucosaminidase [NAG] and 
creatinine. A fresh mid-stream specimen of urine was sent 
for bacteriological examination. 
Blood was drawn from an ante cubital vein for 
estimation of glucose, glycated haemoglobin [HbAl], urea, 
creatinine, albumin and full blood count. Blood pressure was 
measured in the right arm after at least 10 min recumbent 
rest. Diastolic pressure was recorded as the disappearance of 
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sounds [Korotkow phase V]. 
6.3. RESULTS 
Forty patients participated in the study. 
Ages ranged from 31 to 80 years [median 61]. There were 26 
men and 14 women, 30 were Caucasian, 7 Asian, 2 Afro- 
Caribbean and 1 Oriental. Most subjects were normotensive: 6 
patients, however, had diastolic blood pressure greater than 
95 mm Hg. Three of these and 13 others were on anti- 
hypertensive medication. Fifteen patients had complications 
at presentation. Five had peripheral vascular disease, 8 
ischaemic heart disease [all 8 had symptomatic angina 
pectoris and 3 had suffered myocardia1 infarction], 4 had 
clinical neuropathy and 6 had retinopathy. 
There was a decrease in plasma glucose at each 
visit and glycaemic control, judged by HbA1, was 
significantly improved by treatment [Table 6.1]. 
To correct for variability of urinary volume 
the albumin:creatinine and transferrin:creatinine ratios were 
calculated. These are shown with urinary transferrin and 
albumin excretion rates in Table 6.2. There were reductions 
in the urinary transferrin excretion rates over the period of 
the study. ‘Similar results were seen in the urinary 
transferrin:creatinine ratios. There was a trend towards 
reduction of albumin excretion rate during the study but this 
was significant only in patients with abnormally high albumin 
excretion rate at entry. There was no significant change in 
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urinary albumin:creatinine ratios. 
Eleven [28%] patients initially had albumin 
excretion rate greater than 20 [60.8, 20.4-315.3 
median, range]. Ten of these patients had elevated 
transferrin excretion rate. All had significant falls in 
albumin excretion rate with treatment [P < 0.001]. After 6 
weeks treatment there were 6 [15%] patients with elevated 
albumin excretion rate [44.8, 28.2-76.1 median, 
range]. All of these had elevated transferrin excretion 
rates. At 12 weeks only 4 [10%] had elevated albumin 
excretion rate [60.0, 22.1-152.8 median, range] 
three had elevated transferrin excretion rates. Only one 
patient whose initial rate was less than 20 
subsequently had an elevated excretion rate. 
A1M and NAG levels both fell significantly 
after 6 and 12 weeks treatment of diabetes [Table 6.2]. 
Initially there were 21 [53%] patients with 
elevated transferrin excretion rate [0.65, 0.12-10.9 
median, range]. All of these had highly significant falls in 
transferrin excretion rate with treatment [0.34, 0.15-2.24 
at 6 weeks and 0.27, 0.12-1.11 at weeks, P 12 
< 0.0001]. At 6 weeks 12 [30%] patients had elevated 
transferrin excretion rate and at 12 weeks there were 8 
[20%]. Four patients who started with normal transferrin 
excretion rate had elevated rates at subsequent visits. 
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Median urinary transferrin excretion rates 
were similar in patients presenting with or without 
complications [0.09, 0.01-3.12 and 0.12, 0.01-10.94 
respectively, median and range, P = NS]. There 
were similar findings for albumin excretion rates [9.9, 2.4- 
143.5 and 8.75, 1.3-315.3 respectively, P = 
NS]. 
Transferrin excretion rate did not correlate 
with age or disease duration in these patients. There was a 
strong correlation between transferrin excretion rate and 
albumin excretion rate [r=0.86, P < 0.0001] and between A1M 
and NAG [r=0.70, P < 0.0001], transferrin excretion rate and 
A1M [r=0.55, P < 0.0001] and transferrin excretion rate and 
NAG [r=0.46, P < 0.0001] at each visit. There were weaker 
correlations between albumin excretion rate and NAG [r=0.46, 
P < 0.01] and A1M [r=0.44, P < 0.01] at each visit. There 
were correlations between HbA1 levels and each urinary 
protein: transferrin excretion rate [r=0.43, P < 0.0001], 
albumin excretion rate [r=0.33, P < 0.001], A1M [r=0.45, P < 
0.0001] and NAG [r=0.47, P < 0.0001]. There was no 
correlation between transferrin excretion rate and systolic 
or diastolic blood pressure. 
Sixteen patients with hypertension [13 
treated] were considered as a sub-group. Their ages were 
not different from the other patients but they included 8 of 
the 15 patients with complications at presentation. Ten 
Patients had elevated transferrin excretion rate initially 
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and 8 had elevated albumin excretion rate. The numbers fell 
to 4 and 3 patients after 12 weeks treatment. These patients 
do not appear to have behaved differently from those without 
hypertension. 
6.4.DISCUSSION 
6.4.1. Transferrinuria and glycaemic control 
Elevated albumin excretion rates have been 
reported in patients with newly diagnosed, uncontrolled type 
1 or type 2 diabetes mellitus and these return to normal when 
diabetes is controlled [Mogensen and Schmitz 1988b, Martin et 
al 1990b]. I studied urinary transferrin excretion in newly 
diagnosed type 2 diabetic patients and examined the effects 
of glycaemic control. 
Twenty-seven per cent of patients had 
microalbuminuria and 53% had elevated urinary transferrin 
excretion rates at presentation. Prevalence data for 
microalbuminuria in type 2 diabetes are scarce. Mogensen 
[1984b] reported that 12.5% of outpatient diabetics had 
albumin excretion rate between 30 and 140 min”. The 
patients in his study, however, were not newly diagnosed. The 
Bedford study [Keen et al 1969], which was community based, 
found increased prevalence of elevated albumin excretion 
rates at diagnosis in diabetic patients compared with 
borderline diabetic patients or control subjects. A study 
Of 510 patients with type 2 diabetes found that 48% had 
urinary protein excretion > 150 mg [approximately 105 
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[Fabre et al 1982]. 
In my study the number of patients with 
elevated transferrin or albumin excretion rates fell after 
treatment of diabetes. One possible explanation for this 
observation is that hyperglycaemia may cause an osmotic 
diuresis with consequent proteinuria. Control of diabetes by 
reducing the level of glycosuria would subsequently decrease 
proteinuria. I did not measure urinary glucose but the 
findings may be explained in part by the [presumed] high 
urinary levels of glucose in newly diagnosed patients. 
6 .4 .2 .  Altered Renal Function 
An alternative explanation for the decreased 
proteinuria after treatment of diabetes would be altered 
glomerular filtration rate secondary to control of blood 
sugar. Mogensen [1971a] demonstrated elevated glomerular 
filtration rates in type 1 diabetes but found no correlation 
with serum glucose concentration. The same worker also 
demonstrated increased maximum tubular reabsorption capacity 
for glucose in type 1 diabetic patients rendered 
hyperglycaemic by glucose infusion [Mogensen 1971b]. The 
rise in was parallelled by a rise in glomerular 
filtration rate indicating that glomerulo-tubular balance is 
maintained. Similarly, Sandahl-Christiansen et al [1981] 
demonstrated that hyperglycaemia contributes to disturbed 
renal haemodynamics in type 1 diabetes mellitus. These 
Studies indicate that glycaemic control can affect renal 
function. Two groups of workers have published data regarding 
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renal function during and after 12 months improved glycaemic 
control. Wiseman et al [1985] reported normalisation of 
glomerular filtration rate but no change in renal size. 
Feldt-Rasmussen et al [1986] reported reduction of kidney 
size but no change in glomerular filtration rate with no 
change in proteinuria. I do not have adequate data to 
examine the possibility that changes in renal haemodynamics 
were responsible for the reductions in transferrinuria and 
albuminuria seen in the present study. 
In the non diabetic kidney the majority of 
albumin filtered at the glomerulus is reabsorbed in the 
proximal tubule [Dennis and Robinson, 1986]. Increased 
amounts of urinary albumin in diabetes are thought to be a 
consequence of glomerular leak [Abrass 1984]. Transferrin and 
albumin have similar molecular sizes [38A and 36A 
respectively] and weights [77,000 and 66,000 respectively] 
[Tietz 1987]. Increased urinary transferrin loss, therefore, 
may reflect glomerular leak. 
As noted above glycation of serum proteins 
facilitates their transport across the glomerular basement 
membrane. Transferrin, however, is relatively less glycated 
than albumin in diabetes and so its transport should not be 
facilitated at the expense of albumin. If glycated albumin 
and transferrin compete for the same tubular reabsorption 
pathway it is possible that because of differences in 
isoelectric point and molecular conformation albumin is 
preferentially reabsorbed. Increased transferrin excretion 
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rate, therefore, would be most likely the result of decreased 
tubular reabsorption. 
Other workers have demonstrated that there is 
altered tubular function in diabetes [Mathiesen et al 1984, 
Gibb et al 1989]. The suggestion of altered tubular function 
is supported by data from diabetic children [Martin et al 
1990a]. Yaqoob et al [1992] have reported recently that 
tubular damage and transferrinuria precede microalbuminuria 
in type 1 diabetes. I found correlations between transferrin 
and tubular proteins in this study. Although there were 
correlations between the tubular markers and albumin 
excretion rates these were weaker than with transferrin 
excretion rates suggesting that tubular handling is more 
important for transferrin than albumin. 
6.4 .3 .  Transferrinuria and Complications in type 2 Diabetes 
Elevated urinary transferrin excretion rates 
have been reported in patients with type 2 diabetes and 
complications [Cheung et al 1989]. In 15 [37.5%] of my 
patients there was evidence of one or more complications 
[ischaemic heart disease, peripheral vascular disease, 
retinopathy, neuropathy] at diagnosis. There was no 
difference in transferrin or albumin excretion rate between 
Patients with and without these complications. There was no 
difference in transferrin excretion rate or albumin excretion 
rate between patients with and without these complications. 
These patients, however, unlike those of Cheung et al were 
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newly diagnosed and may not have been diabetic for long 
enough to develop complications by the time of the 
study. 
In conclusion, elevated urinary transferrin 
excretion rate is common in newly diagnosed type 2 diabetic 
patients and levels fall with glycaemic control. The 
mechanism for this proteinuria is unknown but may relate to 
altered tubular function. Elevated urinary transferrin 
excretion rate does not appear to be a marker for 
complications in newly diagnosed type 2 diabetic patients. 
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CHAPTER 7 
INCREASED URINARY TRANSFERRIN EXCRETION 
IN EXERCISING NORMOALBUMINURIC 
INSULIN DEPENDENT DIABETIC PATIENTS. 
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7.1. INTRODUCTION 
Presently the most reliable predictor for diabetic 
nephropathy is the presence of microalbuminuria, an albumin 
excretion rate between 20 and 200 in two from three 
timed urine samples in a six month period. Elevated urinary 
transferrin excretion rates, however, may precede elevated 
albumin excretion rates in diabetic children [Martin et al 
1990] and it has been suggested that elevated transferrin 
excretion rates may predict patients at risk of diabetic 
nephropathy [Martin et al 1988, Bernard et al 1988]. No more 
than 40% of type 1 diabetic patients are likely to develop 
nephropathy but I have shown that more than 80% of patients 
have elevated urinary transferrin excretion rates. Hence, 
it is apparent that spontaneous urinary transferrin excretion 
is of low predictive value for this nephropathy. Stimulated 
transferrin excretion, however, may be useful. Vigorous 
exercise is known to provoke elevated albumin excretion rates 
in type 1 diabetic patients who have normal albumin excretion 
rates at rest [Viberti et al 1978, Brun et al 1987, Feldt- 
Rasmussen et al 1985]. To investigate whether transferrin 
may behave in a similar fashion I studied the urinary 
excretion of transferrin in response to exercise in patients 
with uncomplicated type 1 diabetes mellitus. 
7 . 2 .  MATERIALS AND METHODS 
Eight men with Type 1 diabetes mellitus for at 
least five years and eight sex and age matched healthy 
control subjects were studied. The diabetic subjects were 
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normoalbuminuric [urinary albumin excretion rate < 20 min’ 
1 confirmed by at least two timed urine collections], 
normotensive [blood pressure < 160/95 mm Hg], and had no 
retinopathy or clinical evidence of peripheral or autonomic 
neuropathy. The control subjects had no family history of 
diabetes mellitus, hypertension or renal disease. Diabetic 
and control subjects were matched as far as possible for 
their habitual level of exercise. 
7.2.1. Exercise Protocol 
Al 1 subjects underwent a preliminary 
progressive exercise test to determine maximal workload 
capacity. The test commenced at a workload of 50w using an 
electromagnetically braked cycle ergometer [Rodley Elektronik 
820, Sweden]. The workload was then increased by 20w 
until exhaustion. To standardize the physical stress for 
individuals, since not all had the same maximal exercise 
capacity, a steady state sub-maximal test at 50% maximal 
workload was performed not less than 1 week and no more than 
2 months after the maximal test. Data from the steady state 
tests are presented here. 
On the study day subjects attended between 
1300-1600 hours having eaten as normal at midday. Di abet i c 
subjects took their usual insulin. At the start of the study 
period subjects emptied their bladders and drank 200 mL 
water. They then rested recumbent for 1h after which urine 
was collected for estimation of albumin, transferrin, a-i- 
microglobulin, and N-acetyl-ß-D-glucosaminidase content. 
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Blood was drawn with minimal venous stasis for measurement of 
glucose, glycated haemoglobin, plasma electrolytes, urea, 
creatinine, and albumin. Subjects then exercised for 20 min 
at 50% maximal workload. Further blood and urine samples were 
collected immediately after exercise and following one hour's 
rest. To maintain fluid balance during the study subjects 
were given 200ml water plus a volume equivalent to their 
previous hour's urine output to drink per hour. A fresh mid- 
stream specimen of urine was sent for bacteriological 
examination. 
7.2.2. Measurements 
All blood was centrifuged immediately [2000g, 
4 °C] for 10 min. Plasma and urine were frozen and stored at 
-20 °C for later analysis. 
7.3. RESULTS 
Although diabetic and control subjects were 
well matched f o r  age and level of habitual exercise, 
workloads median [range] for steady state exercise were 
slightly higher in the control 260 [150-370w] than diabetic 
group 210 [150-290w], P < 0.05. 
Table 7.1 shows subject characteristics and 
plasma biochemistry at the start of the study. 
Table 7.2 shows urinary flow rates and protein 
excretion rates fo r  diabetic and control subjects at rest, 
immediately after exercise and following one hour's recovery. 
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Urine flows were no different between diabetic and control 
groups and did not alter with exercise. 
In the diabetic group the median transferrin 
and albumin excretion rates after exercise were significantly 
higher than at rest [1.5 vs 0.2 P < 0.001, and 29.8 
vs 7.8 P < 0.001 respectively]. The proportional 
rise in transferrin excretion rate [ > 6 0 0 % ]  was more than 
twice that in albumin excretion rate [<300%]. Median N- 
acetyl-ß-glucosaminidase excretion levels were higher in the 
diabetic than control subjects at rest and after exercise 
[Table 7.2] and did not alter significantly. There was no 
change in microglobulin excretion. 
In the non-diabetic control group albumin 
excretion rose from 6.3 to 11.4 [P < 0.05]. There 
w a s  no alteration in transferrin, N-acetyl-ß-glucosaminidase, 
or a-i- microglobulin excretion. 
After exercise there was a correlation between 
transferrin and albumin excretion rates in the diabetic group 
[r = 0.79, P < 0.02]. No correlation was observed between 
any other proteins. There was no correlation between N- 
acetyl-ß-D-glucosaminidase excretion and glycated 
haemoglobin. 
7 . 4 .  DISCUSSION 
This study confirmed the observation of 
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increased urinary albumin excretion rate following exercise 
in type 1 diabetic patients [Viberti et al 1978, Brun et al 
1978, Feldt-Rasmussen et al 19851. The finding of increased 
transferrin excretion in diabetic subjects following exercise 
is novel. Although quantitatively much less transferrin than 
albumin is excreted there is a proportionally far greater 
increase. Although there was a slight rise in albumin 
excretion following exercise there was no increase in urinary 
transferrin excretion in the control group. This suggests 
altered handling of transferrin in the diabetic state. 
Albumin excretion rate has been shown to increase on exercise 
in poorly controlled diabetes. The same may be true for other 
proteins, including transferrin, but there are no data 
regarding this. The increase in protein excretion could not 
have been a consequence of altered urine flow rates since 
there was no difference between diabetic and control groups 
nor within the groups during the study. 
7.4.1. Evidence for Renal Tubular Dysfunction 
Viberti et al [1978] interpreted their 
findings of increased urinary albumin excretion but normal 
microglobulin excretion [a marker of renal tubular 
function] following exercise as evidence for a glomerular 
leak of albumin. A study of non-diabetic children and 
adolescents reported similar results [Huttunen et al 1981]. 
Poortmans and co-workers [1988], however, found that there 
was a pattern of proteinuria suggestive of mixed glomerulo- 
tubular loss during an exercise test in diabetic subjects 
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given lysine, an amino acid which blocks tubular reabsorption 
of filtered protein. The finding of increased albumin 
excretion following exercise in the diabetic group in the 
present study is evidence for a glomerular leak. Data from 
the cross sectional study showed a correlation between 
urinary excretions of transferrin and N-acetyl-ß-D- 
glucosaminidase [a marker of renal tubular function] 
suggesting a tubular component to transferrin loss. 
7 . 4 . 2 .  N-acetyl-ß-D-glucosaminidase excretion 
In the present study N-acetyl-ß-D- 
glucosaminidase excretion was higher in the diabetic than the 
control group at rest and after exercise. The finding of 
increased N-acetyl-ß-D-glucosaminidase excretion at rest in 
diabetic subjects with proteinuria has been taken as evidence 
of tubular dysfuction [Ratzmann et al 19881. Increased N- 
acetyl-ß-D-glucosaminidase excretion following treadmill 
exerci se and a correlation between N-acetyl-ß-D- 
glucosaminidase and glycated haemoglobin levels has been 
reported in diabetic children [Brouhard et al 1985]. Neither 
N-acetyl-ß-D-glucosaminidase nor -microglobulin excretion 
altered with exercise in my study; there was no correlation 
with serum levels of glycated haemoglobin. These observations 
suggest that any effect of exercise on tubular protein leak 
is small, if present at all. 
The mechanism[s] underlying the increased loss 
of protein following exercise is unknown. Ala-Houhala and 
Pasternak [1987], and Ala-Houhala [1990] demonstrated 
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decreased glomerular filtration rate and renal blood flow 
with net increased filtration fraction and fractional 
clearance of dextrans of radius greater than 4.8nm after 
exercise in subjects with diabetic nephropathy. These 
results indicate that there is increased glomerular 
permeability as a consequence of altered renal haemodynamics. 
Loss of the negative charge on glomerular capillary walls is 
important in the development of diabetic proteinuria 
[Parthasarathy and Spiro 1982]. Results from animal work 
reveal a reduction in this charge following exercise 
[Zambraski et al 1981]. This may explain partially the 
development of post exercise proteinuria in the human. The 
anionic glomerular basement membrane represents less of a 
barrier to the passage of cationic than anionic molecules. 
Since native albumin, is more anionic than transferrin [pI 
albumin 4.9, pI transferrin 5.8] it should be preferentially 
retained by the glomerular basement membrane. My observation 
of increased transferrin excretion after exercise is not in 
keeping with this mechanism and suggests that haemodynamic 
factors may be more important in this setting. 
In summary, I have demonstrated increased 
transferrin excretion in exercising diabetic subjects without 
evidence of complications. There was no rise in urinary 
transferrin excretion following exercise in a well matched 
control group. In the diabetic group the proportional 
increase in transferrin excretion was greater than for 
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albumin and there is evidence for altered glomerular leak in 
these patients. The data suggest that even patients with 
apparently uncomplicated diabetes mellitus may have abnormal 
renal function. Elevated urinary transferrin excretion rates 
after exercise may be better discriminators than elevated 
urinary albumin excretion rates. The mechanism underlying the 
exercise induced increase in transferrin excretion remains to 
be elucidated. 
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CHAPTER 8 
THE EFFECTS OF AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND 
CALCIUM CHANNEL BLOCKER ON URINARY TRANSFERRIN EXCRETION IN 
DIABETIC PATIENTS WITH ELEVATED ALBUMIN EXCRETION RATES. 
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8.1. INTRODUCTION 
I have demonstrated elevated transferrin excretion 
rates in patients with type 1 diabetes mellitus and this may 
indicate impaired renal function. My second study showed 
that newly diagnosed type 2 diabetic patients have increased 
transferrin excretion rates and the third that urinary 
transferrin excretion can be provoked by exercise in patients 
with uncomplicated type 1 diabetes. Despite these apparent 
similarities with the behaviour of albumin, transferrin's 
relationship with markers of renal tubular function suggests 
that the diabetic kidney handles it in a different fashion 
from albumin. 
Several groups have reported decreases in 
urinary albumin excretion in hypertensive and normotensive 
diabetic patients treated with angiotensin converting enzyme 
[ACE] inhibitors [Taguma et al 1985, Marre et al 1988]. I 
have studied the effects of an ACE inhibitor on urinary 
transferrin excretion in normotensive diabetic patients with 
microalbuminuria and hypertensive diabetic patients with 
macroalbuminuria. 
8.2. PATIENTS AND METHODS 
Subjects had micro- or macroalbuminuria and had 
been identified from an extension of the screening programme 
described earlier. There were two study protocols which are 
described more fully in Chapters 11 and 12. 
The first was a double blind placebo 
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controlled study of the effects of an ACE inhibitor, 
lisinopril, in normotensive [BP < 160/90 mm Hg], 
microalbuminuric [AER, > 20 but < 200 min-'] 
patients. Patients gave informed consent and followed the 
protocol as detailed in Figure 8.1. Briefly, after a two week 
placebo run in period those whose compliance was worse than 
80% were excluded and the remainder were randomised double 
blind to receive lisinopril or placebo. Patients randomised 
to lisinopril received a test dose of 2.5 mg and then 
lisinopril 10 mg daily for the duration of the study [48 
weeks]. Those randomised to placebo continued placebo 
matching lisinopril 10 mg daily. Patients were reviewed on 
four further occasions at 12 week intervals. 
The second [Fig 8.2] was a double blind, 
double dummy comparison of lisinopril with nifedipine, in 
hypertensive [blood pressure 160/90 mm Hg off treatment] 
patients with persistent macroproteinuria [AER 200 min- 
']. After a two week placebo run in period to exclude those 
with compliance less than 80% patients were randomised double 
blind to receive lisinopril or nifedipine. Patients 
randomised to lisinopril received a test dose of 2.5 mg with 
placebo matching slow release nifedipine 10mg twice daily 
followed by lisinopril 5 mg daily with placebo matching slow 
release nifedipine 10 mg twice daily [Visit 3]. Patients 
randomised to nifedipine were given a test dose of slow 
release nifedipine 10 mg twice daily and placebo matching 2.5 
mg lisinopril followed by slow release nifedipine 10 mg twice 
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daily and placebo matching lisinopril 5 mg one tablet daily. 
All were reviewed three times at three week intervals. The 
dose of lisinopril was increased stepwise to 10 mg [Visit 4] 
or 20 mg daily [Visit 5] and that of nifedipine to 20 mg 
twice daily [Visit 4] or 40mg twice daily [Visit 5] as 
necessary with the aim of achieving diastolic blood pressure 
90 mm Hg. Antihypertensive medication was continued for a 
further eight weeks at which time the study was terminated 
[Visit 7]. 
In both studies blood pressure was measured at 
each visit after at least 10 minutes rest. Two readings were 
taken from the right arm, at heart level, using a Hawksley 
random zero sphygmomanometer and the mean was recorded. 
Diastolic blood pressure was taken as Korotkoff phase 5. 
Mean arterial blood pressure [MAP] was calculated as 
diastolic blood pressure + pulse pressure/3. 
Timed overnight urine collections were made 
immediately prior to clinic visits. 
8.3.RESULTS 
8.3.1. Normotensive Patients 
Thirty-two patients entered the first study. 
Three lisinopril treated and 2 placebo treated patients were 
withdrawn because of adverse effects or failure to attend for 
follow up. Hence, 27 patients [12 lisinopril, 15 placebo1 
completed the study. The groups were well matched for age, 
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sex, weight and treatment of diabetes [Table 8.1]. 
At entry to the study 10 lisinopril treated and 15 
placebo treated patients had elevated transferrin excretion 
rates [TER > 0.11 as previously defined]. Excretion 
rates rose in 12 placebo treated and 3 lisinopril treated 
patients [Fig 8.3] although median transferrin excretion rate 
did not alter appreciably in either group [Table 8.2]. 
Mean [±SD] albumin excretion rate fell 
progressively in the lisinopril group from 58.4 [26.7] 
at baseline to 26.8 [26.8] [P < 0.01] after 48 
weeks treatment and rose in the placebo group [102.7 [79.9] 
vs. 112.9 [76.7] P = NS]. This represented 
a change in mean albumin excretion rate of -34.3 [30.9] 
for the lisinopril group and +12.8 [88.4] for 
the placebo group. After 48 weeks treatment 7 lisinopril 
treated patients were normoalbuminuric and 5 were 
microproteinuric; 3 placebo treated were normoalbuminuric, 9 
microalbuminuric and 3 were macroproteinuric [Fig 8.3]. 
Transferrin and albumin excretion rates did not 
correlate in either group at the beginning of the study but 
did correlate at visit 7 [r = 0.53, P < 0.05], in the placebo 
group. 
8.3.2. Hypertensive Patients 
Fourteen patients were randomised to each 
treatment. Analysis of transferrin results is based on 12 
96 


patients from each group for whom there were complete data. 
The groups were well matched for age, weight, and sex [Table 
8.3]. 
No patient had normal transferrin excretion rate 
at the start of the study but one lisinopril treated patient 
had normal transferrin excretion rate at the end of the 
study. Median transferrin excretion rate fell from 15.3 
to 11.2 [P = NS] for lisinopril treated 
patients but rose from 14.3 to 31.5 [P = 
NS] for those receiving nifedipine [Table 8.3]. There were no 
significant differences in transferrin excretion rate between 
lisinopril and nifedipine treated groups at any visit [Fig 
8.4]. 
Albumin excretion rate fell [from 738.7 ± 635.2 fg 
to 644.6 ± 965.2 between visits 2 and 7 in 
the lisinopril treated group. albumin excretion rate rose 
from 981.2 ± 1022.2 to 1072.5 ± 908.5 in 
the nifedipine treated group. There was, however, no 
significant difference between groups. 
There was no correlation between transferrin 
excretion rate and albumin excretion rate at any time in the 
lisinopril treated group but there were strong correlations 
at visits 6 and 7 [r=0.98, r=0.99, respectively, P < 0.01] in 
nifedipine treated patients. 
There was no correlation between transferrin 
excretion rate and systemic blood pressure nor between change 
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in transferrin excretion rate and change in blood pressure in 
either group. 
Blood pressure [mean ± SD] was lower in both 
groups at visit 7 compared with visit 2 [143/88 ± 17/13 mm Hg 
vs 166/99 ± 23/9 mm Hg for lisinopril treated, and 148/85 ± 
25/10 mm Hg vs. 165/99 ± 21/7 mm Hg for nifedipine treated, 
Table 8.5]. Blood pressures were not significantly different 
between groups throughout the study [Fig 8.5]. 
8.4. DISCUSSION 
I have performed two studies of the effects of 
angiotensin converting enzyme [ACE] inhibition on urinary 
transferrin excretion. These addressed the questions of 
whether ACE inhibition has an effect on transferrin excretion 
in normotensive diabetic patients; whether lowering blood 
pressure in hypertensive diabetic patients affects 
transferrin excretion; whether the effect, if present, is 
specific to ACE inhibitors; and whether transferrin and 
albumin behave in the same way in diabetic patients. 
For the normotensive patients the lisinopril 
and placebo treated groups were well matched for age, sex, 
weight and treatment of diabetes at entry to the study. 
Taking the upper limit of normal for urinary transferrin 
excretion as 0.11 I found, as in previous studies, 
that the majority of diabetic patients had elevated excretion 
rates. 
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During the intervention studies median values for 
transferrin excretion did not alter significantly in either 
group although they showed a tendency to rise in placebo 
treated patients and to fall in those treated with 
lisinopril. These data suggest that transferrin excretion 
can be modified by ACE inhibition in this patient population. 
Similarly, there were differences between albumin excretion 
rates in placebo and lisinopril treated groups. A 
correlation between transferrin excretion and albumin 
excretion rate, however, was seen only in the placebo group. 
A correlation between transferrin and albumin excretion rates 
was noted in the cross-sectional data from the screening 
study of diabetic patients. The absence of a correlation 
between these proteins in patients taking ACE inhibitors 
suggests that the drug has in some way altered the renal 
handling of one or the other to a greater extent. The 
mechanism[s] by which transferrin excretion is altered by ACE 
inhibition remains to be defined but is probably the same as 
that responsible for redcing albuminuria i.e. reduction of 
intra-glomerular capillary pressure. 
As in the normotensive diabetic patients 
median transferrin excretion fell in lisinopril treated 
hypertensive diabetic patients although again the change .in 
excretion rate was not significant. Conversely there was a 
tendency for transferrin excretion to rise, insignificantly, 
in nifedipine treated patients. Similar changes were found 
for albumin. There were significant falls in systemic blood 
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pressure in both lisinopril and nifedipine treated groups. 
There was, however, no correlation between reduction in 
transferrin excretion and reduction of systemic blood 
pressure. These data suggest that, although there is a 
tendency for transferrin excretion to fall in ACE inhibitor 
treated patients when blood pressure is reduced, reduction of 
transferrin excretion depends upon a specific intra-renal 
effect of ACE inhibition [reduction of intra-glomerular 
capillary pressure]. Nifedipine appears not to be useful in 
this setting. 
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THE KIDNEY IN DIABETES MELLITUS: 
PART II 
THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 
HYPERTENSION, 
AND THE ROLE OF 
ANGIOTENSIN CONVERTING ENZYME INHIBITORS 
IN THERAPY 
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CHAPTER 9 
BLOOD PRESSURE IN DIABETIC NEPHROPATHY: 
1. ACTIVITY OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 
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9.1. INTRODUCTION 
There have been varying reports of the activity of 
the Renin-Angiotensin-Aldosterone system in patients with 
diabetes mellitus. Depending upon whether tha patient has 
renal impairment or hypertension the activity has been 
variously reported as normal [O'Hare et al 1988, Feldt- 
Rasmussen et al 1987], increased [De Chatel et al 1977, 
Burden and Thurston 1979] or  decreased [Tuck et al 1979, 
Christlieb et al 1976a]. There is evidence from animal 
studies that angiotensin II, a component of the Renin- 
Angiotensin-Aldosterone system, may affect renal vascular 
tone and play a role in proteinuria [Yoshioka et al 1986]. I 
investigated the relationship of activity of the Renin- 
Angiotensin-Aldosterone system to proteinuria in type 1 
diabetic patients. 
9.2. Patients and Protocol 
Patients were studied as part of the screening of 
type 1 diabetic subjects as described in Chapter 4 .  They 
attended at 09.00h having taken their usual breakfast and 
insulin. All were taking their usual diet and none was 
taking a diet restricted in salt or protein. Those taking 
diuretic or antihypertensive drugs were asked to stop them 2 
weeks prior to the study day. Patients were instructed to 
empty their bladders and a cannula was inserted into an 
antecubital vein. They remained recumbent for the next 2h 
and were given 200 ml water per hour to drink. All urine 
passed during this time was collected and aliquots saved and 
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frozen at -20 °C for later estimation of albumin and 
electrolytes. A fresh sample of urine was sent for 
bacteriological examination. 
After at least 30 min rest 10 ml blood was drawn 
from the indwelling catheter into vacuum tubes containing 
heparin and immediately placed on ice. these were spun at 
2000g for 30 min at 4 °C and the plasma frozen at -70 °C for 
later estimation of renin activity and aldosterone content. 
Further samples were drawn for estimation of plasma glucose, 
glycated haemoglobin electrolytes and creatinine. 
After a further period of rest supine blood 
pressure was recorded twice in the right arm and the mean of 
these recorded. 
9.3. RESULTS 
In this study 52 [71%] patients were 
normoalbuminuric, 13 [18%] microalbuminuric, and 8 [11%] 
macroalbuminuric. All groups were comparable for age, 
plasma glucose, and creatinine but disease duration was 
longer in the macroalbuminuric group [Table 9.1]. 
Median plasma renin activity was increased ,in 
patients with micro- or macro-albuminuria compared with those 
with normoalbuminuria [Table 9.2]. There was no correlation 
between plasma renin activity and albumin excretion in any 
group. 
Median plasma aldosterone was similar in each 
group [Table 9.2]. Plasma and urinary electrolytes and 
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urinary sodium excretion rates were not significantly 
different between groups. 
Mean systolic blood pressure was higher in the 
macro- than normo- group [141 ± 27 vs 116 ± 13 mm Hg, P < 
0.01] but not different from the microalbuminuric [121 ± 16 
mm Hg, P = NS]. There were no inter group differences for 
diastolic blood pressure. Overall there was a weak 
correlation between systolic blood pressure and albumin 
excretion rate [r = 0.23, P < 0.05]. 
9.4. DISCUSSION 
Compared with the normoalbuminuric group 
those with elevated albumin excretion rates had elevated 
plasma renin activity but there was no correlation between 
the two variables. Overall there was a weak correlation 
between systolic blood pressure and albumin excretion rate 
but not wih plasma renin activity. these observations 
although on a small number of patients suggest that altered 
plasma renin activity is not responsible for the hypertension 
seen in diabetic nephropathy. 
In a similar study Feldt-Rasmussen et al 
[1987] reported no difference in plasma active renin levels 
between groups with different albumin excretion rates 
although there was a higher plasma inactive renin level in 
macroproteinuric patients. No patient in my study was 
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taking a drug known to influence plasma renin activity but it 
is possible that a biological effect persisted in those who 
had stopped medication. This is unlikely, however, since 
significant differences in plasma renin activity between 
normo- and microalbuminuric groups persisted even after those 
who had been taking medication were excluded from the 
analysis [data not shown]. No similar comparison involving 
macroproteinuric patients was possible since all had been 
taking drugs known to alter plasma renin activity. 
In a study of 31 diabetic patients with 
proliferative retinopathy more than 50% had microalbuminuria 
[Drury and Bodansky 1985]. The median plasma renin activity 
in the albuminuric group was raised compared with those with 
normal albumin excretion rates, and the former group had lost 
the normal inverse relationship between blood pressure and 
plasma renin activity. Leutscher et al [1985] found that 
plasma inactive renin was elevated in patients with 
proteinuria but they did not correlate either variable with 
blood pressure. 
In my study neither plasma nor urinary 
electrolyte concentrations nor urinary sodium excretion rate 
differed between groups. Total body sodium, a factor 
important in determining plasma renin activity, was not 
measured but is increased in diabetes mellitus [De Chatel et 
al 1977, Feldt-Rasmussen et al 1987]. Despite normal plasma 
biochemistry there may have been inter-group differences for 
exchangeable sodium. There were no significant inter group 
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differences for plasma aldosterone and all levels were within 
the laboratory's normal reference range. Others have 
reported comparable levels of aldosterone in diabetic 
patients and normal control subjects and an apparent 
separation between renin and aldosterone secretion [De Chatel 
et al 1977, Feldt-Rasmussen et al 1987]. Insulin is known 
to promote renal tubular reabsorption of sodium [De Fronzo 
1981]. This may explain why type 1 diabetic patients [with 
high levels of exogenous insulin] have normal or low levels 
of plasma aldosterone in the face of a raised exchangeable 
body sodium. Hyporeninaemic hypoaldosteronism has been 
reported in diabetic nephropathy [Tuck et al 1979]. This 
was not observed in any patient in the present study despite 
the fact that several had a protein leak of several grams per 
day. None, however, had biochemical evidence of renal 
decompensation. 
Angiotensin II levels were not measured but would 
be expected to be elevated in parallel with plasma renin 
activity. Angiotensin II may promote proteinuria by altering 
intraglomerular haemodynamics [Yoshioka et al 1986]. Other 
work has shown increased systemic vasopressor responsiveness 
to infused angiotensin II in patients with uncomplicated type 
1 diabetes [Drury et al 1984]. Thus there is a pathway 
whereby increased plasma renin activity, and consequently 
angiotensin II, may in turn promote not only proteinuria but 
also an accompanying rise in systolic blood pressure. 
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CHAPTER 10 
BLOOD PRESSURE IN DIABETIC NEPHROPATHY: 
2.THE BLOOD PRESSURE RESPONSE TO EXERCISE IN PATIENTS WITHOUT 
EVIDENCE OF COMPLICATIONS 
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10.1. INTRODUCTION 
Hypertension is common in type 1 diabetes 
mellitus and may relate to the development of nephropathy, 
although it is still unclear whether it precedes or is 
secondary to this complication [Mathiesen et al 1990]. A n  
exaggerated systolic blood pressure response to exercise in 
type 1 diabetes mellitus has been reported and related to the 
degree of albuminuria [Christensen 1984], but might also 
result from abnormalities of catecholamines, plasma renin 
activity [PRA] or atrial natriuretic peptide [ANP]. Total 
body sodium is increased and resting catecholamines may be 
suppressed in type 1 diabetes mellitus [Feldt-Rasmussen et al 
1987]. Studies of plasma renin activity in type 1 diabetes 
mellitus are conflicting. Activity has been reported as low 
[Christlieb et al 1976, Tuck et al 1979], normal [Feldt- 
Rasmussen 1987, O'Hare et al 1988] and high [De Chatel et al 
1977]. I have found increased plasma renin activity in 
diabetic patients with raised albumin excretion rates 
[Chapter 9]. Others have reported low plasma renin activity 
and raised levels of ANP in diabetic patients with poor 
glycaemic control [Bell et al 1989]. 
The aims of this study were to determine the 
blood pressure response to exercise in uncomplicated diabetes 
and to investigate the relationship between such response and 
the above biochemical parameters. 
10.2. SUBJECTS AND METHODS 
Eight men with type 1 diabetes mellitus for at 
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least five years and eight sex and age matched healthy 
control subjects were studied. The diabetic subjects were 
normoalbuminuric [urinary albumin excretion rate less than 20 
confirmed by at least two timed urine collections], 
normotensive, and had no retinopathy [judged by 
ophthalmoscopy through dilated pupils] or clinical evidence 
of neuropathy. None had autonomic neuropathy [normal heart 
rate responses to standing, deep breathing and the Valsalva 
manoevre and blood pressure response to standing]. None of 
the control subjects had a family history of diabetes and no 
evidence of retinopathy, autonomic or peripheral neuropathy. 
Al 1 subjects underwent a preliminary 
progressive exercise test to determine maximal workload 
capacity. The test commenced at a workload of SOW using an 
electromagnetically braked cycle ergometer [Rodley Elektronik 
820, Sweden]. The workload was then increased by 20w 
unti 1 exhaust ion. Not less than 1 week and no more than 2 
months after the maximal test subjects performed a steady 
state sub-maximal test at 50% maximal workload. Data from 
the steady state tests are presented here. 
On the study day subjects attended between 
1300-1600 hours having eaten as normal at midday. Diabetic 
subjects took their usual insulin. At the start of the study 
period subjects emptied their bladders and drank 200 ml 
water. They then rested recumbent for 1h after which urine 
was collected for estimation of sodium excretion. Venous 
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blood was drawn for measurement of glycated haemoglobin, 
plasma electrolytes, urea, glucose, albumin, atrial 
natriuretic peptide, noradrenaline, adrenaline, dopamine and 
plasma renin activity. Subjects then exercised for 20 min at 
50% maximal workload. Further blood and urine samples were 
collected immediately after exercise and following one hour's 
rest. To maintain fluid balance during the study subjects 
were given 200ml water plus a volume equivalent to their 
previous hour's urine output to drink per hour. 
Blood pressure and heart rate were measured 
with a computerised exercise testing system [Magna 88, PK 
Morgan, Rainham, Kent] at the end of the initial rest period 
and then at five minute intervals throughout exercise. 
All blood was immediately centrifuged [2000g, 
4 °C] for 10 min. Plasma and urine were frozen and stored at 
-20 °C for later analysis. 
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10.3. RESULTS 
Workloads for steady state exercise were higher in 
the control [260, 150-370w] than diabetic group [210, 150- 
290w, p<0.05]. 
Table 10.1 shows subject characteristics and 
biochemistry at the start of the study. 
Table 10.2 shows heart rate and blood pressure 
responses to exercise. Resting and post-exercise heart 
rates were similar in both groups. Resting systolic blood 
pressure was slightly higher in the diabetic than control 
group [NS] and showed an exaggerated response to exercise 
[p<0.01]. Diastolic blood pressure was higher in the diabetic 
group at rest and following exercise [p<0.05]. 
Table 10.3 lists the plasma and urine electrolytes 
and Table 10.4 the changes in catecholamines, plasma renin 
activity and ANP during the study. Resting urinary sodium 
excretion was raised in the diabetic group and fell during 
exercise [p<0.05]. Plasma albumin was lower in diabetic than 
control subjects [p<0.05] but rose significantly in both 
groups during exercise [p<0.05]. There were no significant 
changes in adrenaline or dopamine levels in either group 
during the study. Resting noradrenaline levels were lower in 
the diabetic group [p<0.02] and showed a marginally greater 
response to exercise overall [NS]. This difference was 
accounted for by the marked rise in noradrenaline levels [178 
and 307%] during exercise in the two diabetic patients with 
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Plasma renin the highest rise in systolic blood pressure. 
activity levels did not differ significantly between the two 
groups at rest or following exercise in the two groups. 
Resting atrial natriuretic peptide levels were lower in the 
diabetic group [p<0.02]. Levels rose significantly during 
exercise in both diabetic [p<0.03] and control [p<0.05] 
groups. There was a significant positive correlation between 
atrial natriuretic peptide levels and increasing duration of 
diabetes [r=0.71, p<0.05]. No correlation was found between 
any of the other variables studied. 
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10.4 DISCUSSION 
The higher resting diastolic and exaggerated rise 
in systolic pressure on exercise in this patient group 
supports a previous report [Torffvit et al 1987], but is at 
variance with another [Kelleher et al 1987]. In the latter 
study, however, subjects exercised for only 6 minutes, 
whereas in the present study the differences were only 
apparent in the last 5 minutes of exercise. Autonomic 
dysfunction is unlikely to account for the results since the 
diabetic and control groups showed no significant difference 
in heart rate response and there was no evidence of autonomic 
neuropathy on formal testing. One previous study, however, 
did report impairment of heart rate response to exercise in 
teenage patients with only short duration of disease 
[Johanssen et al 1987]. Another possible explanation for the 
BP rise is the enhanced noradrenaline response to exercise 
reported in type 1 diabetes mellitus [Tamborlane et al 1979] 
and noted in some patients in this study. Increased vascular 
sensitivity to catecholamines has been demonstrated in type 1 
diabetes mellitus by an augmented blood pressure response to 
noradrenaline infusion. This in turn may be normalised by 
chlorthalidone suggesting that sodium retention contributes 
to the increased catecholamine sensitivity and hypertension 
in type 1 diabetes mellitus [Weidmann et al 1979]. Exercise- 
induced hypertension may be the first manifestation of this 
hypersensitivity. Indeed, type 1 diabetes mellitus is 
associated with increased total body sodium, which is not 
explained by changes in aldosterone, angiotensin II or 
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catecholamines [Feldt-Rasmussen 1987]. 
There was no difference in basal urinary sodium 
excretion between the groups. The diabetic group, however, 
showed a significant reduction following exercise. This may 
be due to increased activity of the renin-angiotension- 
aldosterone system although the rise in plasma renin activity 
following exercise was only marginally higher in the diabetic 
than the control group. Increased vascular sensitivity to 
angiotensin II in type 1 diabetes mellitus has been 
demonstrated, however, even in the presence of normal plasma 
renin activity levels [Christlieb et al 1976b]. Increased 
sensitivity to aldosterone may account for the decreased 
sodium excretion seen in this diabetic group. The similar 
plasma renin activity response to exercise in both groups 
indicates that the exaggerated systolic blood pressure 
response was not due to increased renin secretion. It may, 
however, reflect enhanced sensitivity to angiotensin II. 
Reduced resting atrial natriuretic peptide 
levels in uncomplicated diabetes have not been reported 
previously. There was, however, an appropriate response to 
exercise in this study. A previous study showed basal ANP 
levels to be similar in type 1 diabetes mellitus and 
controls, although 5 of the 7 diabetic subjects had 
microvascular or neuropathic complications [Donckier et al 
1989]. In another study of uncomplicated subjects with type 
2 diabetes basal ANP levels were not significantly lower than 
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controls [McKnight et al 1989]. Increased ANP levels have 
been reported in a group of poorly controlled patients with 
type 2 diabetes mellitus [Bell et al 1989] and may be 
secondary to sodium retention and hypertension [Dodson and 
Horton 1988]. Confirmation of the finding of reduced ANP 
levels in the diabetic group might suggest that ANP has a 
contributory role in the development of increased body sodium 
and diastolic hypertension in type 1 diabetes mellitus. 
This study confirms previous reports of low 
resting noradrenaline levels and reduced plasma albumin in 
type 1 diabetes mellitus, the causes of which are unclear, 
the latter being unrelated to plasma volume or urinary 
albumin excretion [Kelleher et al 1987]. 
In conclusion, exercise provokes an 
exaggerated systolic blood pressure response and reduction in 
urinary sodium excretion in normoalbuminuric type 1 diabetic 
patients. Both findings may reflect increased sensitivity to 
the renin-angiotensin-aldosterone system despite normal 
plasma renin activity levels. The highest blood pressure 
changes were associated with an enhanced noradrenaline 
response despite lower basal levels in the diabetic group. 
Reduced atrial natriuretic peptide levels may stimulate 
sodium retention and increased diastolic blood pressure in 
early type 1 diabetes mellitus. The presence of these changes 
in a group of otherwise uncomplicated type 1 diabetic 
subjects suggests they are a consequence of the diabetic 
state rather than the development of micro- or macrovascular 
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complications. Assessment of the possible contribution of 
these abnormalities to the development of hypertension in 
type 1 diabetes awaits the results of prospective studies. 
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CHAPTER 11 
STUDIES OF 
ANGIOTENSIN CONVERTING ENZYME [ACE] INHIBITION 
IN DIABETES MELLITUS 
ON RENAL FUNCTION AND PROTEINURIA 
1. OVERT NEPHROPATHY 
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11.1. INTRODUCTION 
As noted previously, up to 40% of type 1 [insulin 
dependent] diabetic patients may develop nephropathy 
[Andersen et al 1983, Parving et al 1988a]. Comparable 
studies have not been made in type 2 [non-insulin dependent] 
diabetes but a population based study in North America 
reported a prevalence of 24.6% after twenty years’ disease 
duration [Ballard et al 1988]. In the United Kingdom there 
are an estimated 600 cases of end stage renal failure as a 
consequence of diabetes mellitus each year [Joint Working 
Party on Diabetic Renal Failure 1988]. 
Lowering elevated blood pressure is the only 
manouevre which has been shown reliably to slow the 
progression of diabetic nephropathy [Mogensen 1976, 
1982; Parving et al 1983, 1989]. A wide variety of agents 
[diuretics, vasodilators, ß-adrenergic blockers, calcium 
channel blocking drugs, and angiotensin converting enzyme 
[ACE] inhibitors] have been used to treat hypertension in 
diabetic nephropathy but few studies have compared drugs. 
Calcium channel blockers have been advocated for the 
treatment of hypertension in diabetes but ACE inhibitors, 
because of their renal effects, especially lowering of intra- 
glomerular pressure, may be particularly suitable [Parving et 
al 1988b]. A recent study, however, found no difference 
between these classes of drugs [Baba et al 1989]. To 
investigate this further I conducted a prospective randomised 
double blind study to compare the effects of an ACE inhibitor 
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[lisinopril] with those of a calcium channel blocker 
[nifedipine] on renal function and blood pressure in 
hypertensive, macroproteinuric diabetic patients. 
11.2. SUBJECTS AND METHODS 
Male and female patients aged 18-70 years with 
type 1 or type 2 diabetes mellitus were recruited from the 
diabetic-renal clinic. Patients had Albustix positive 
proteinuria and all had persistent macroproteinuria [albumin 
excretion rate [AER] 200 confirmed in at least 
two timed overnight urine collections during a six month 
period. All had resting diastolic blood pressure 90-115 mm Hg 
off treatment . Macroproteinuric patients taking 
antihypertensive medication were eligible for entry to the 
study if their blood pressure was elevated after 1 month 
without treatment. 
Exclusion criteria were: malignant or accelerated 
hypertension, or secondary hypertension of any aetiology; 
heart failure, aortic outflow obstruction, unstable angina, a 
history of myocardia1 infarction in the preceding 3 months; 
known renal disease other than diabetic nephropathy, plasma 
creatinine 200 , low protein diet; systemic 
malignancy; clinically significant abnormality of hepatic, 
haemopoietic or endocrine function; women of childbearing 
potential not using a medically acceptable method of birth 
control; a history of hypersensitivity to ACE inhibitors or 
nifedipine. Patients taking any of the following medications 
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were excluded; aldose reductase inhibitors, myoinositol, 
steroids, gold, penicillamine, non steroidal anti-inflamatory 
agents, monoamine oxidase inhibitors, appetite suppressants, 
lithium, vasopressor nasal decongestants, cimetidine. 
Patients fulfilling the inclusion criteria gave informed 
consent and then followed the study protocol as detailed in 
Figure 11.1. 
All patients entered the two week placebo run in 
period to assess compliance [Visit 1]. Tablets were counted 
at visit 2 and patients whose compliance was less than 80% 
were excluded from final data analysis. Patients were 
randomised double blind to receive lisinopril or nifedipine 
according to separate schedules for type 1 and type 2 
diabetes. Those randomised to receive lisinopril were given a 
test dose of 2.5 mg with placebo matching slow release 
nifedipine 10mg twice daily. They were reviewed the following 
day and if the test dose had been tolerated without side 
effects were prescribed lisinopril 5 mg daily with placebo 
matching slow release nifedipine 10 mg twice daily [Visit 3]. 
Patients randomised to receive nifedipine were given a test 
dose of slow release nifedipine 10 mg twice daily and placebo 
matching 2.5 mg lisinopril. If on review they had no side 
effects they were prescribed slow release nifedipine 10 mg 
twice daily and placebo matching lisinopril 5 mg once daily. 
All patients were reviewed on three further 
occasions at three week intervals. At each visit, after at 
least 10 minutes rest, blood pressure was measured twice in 
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the right arm at heart level using a Hawksley random zero 
sphygmomanometer. The mean of these readings was calculated 
and with the aim of achieving a diastolic blood pressure 90 
mm Hg [Korotkoff phase 5] the dose of lisinopril was 
increased stepwise to 10 mg [Visit 4] or 20 mg daily [Visit 
5] and that of nifedipine to 20 mg twice daily [Visit 4] or 
40mg twice daily [Visit 57. Antihypertensive medication was 
continued for a further eight weeks at which time the study 
was terminated [Visit 71. At each visit mean arterial blood 
pressure [MAP] was calculated. 
11.2.1. Renal Function. 
Glomerular filtration rate [GFR] and renal blood 
flow [RBF] were measured at visits 2 and 7 as the rates of 
disappearance from plasma of and 
after simultaneous single injections of each isotope as 
described previously. 
11.2.2. Proteinuria 
Timed overnight urine collections were made at 
visits 1, 2, 6 ,  and 7. Albumin concentration was measured 
by radioimmunoassay and the albumin excretion rate [AER] was 
calculated using the formula 
AER = CV 
T 
[where C is the urinary albumin concentration, V is the 
volume of urine passed during the collection and T is the 
time of the collection]. Fractional albumin clearance was 
calculated as the ratio urinary clearance albumin:GFR. 
122 
11.2.3.Haematology and Biochemistry 
Blood was taken at visits 2, 4,  6 ,  and 7 for 
measurement of haemoglobin and haematocrit, creatinine, 
albumin, urea, sodium and potassium. Blood was drawn at 
visits 2, 4 ,  5, 6 ,  and 7 for measurement of plasma glucose 
and glycated haemoglobin reference range 5.0-9.0%]. 
11.2.4. Statistical analysis. 
For blood pressures, GFR, RBF, ERPF, FF, and 
RR changes from baseline [visit 7 minus visit 2] were 
analysed using the analysis of covariance [ANCOVA] technique: 
the baseline [visit 2] values were further included in the 
model as the covariate as this was found to substantially 
contribute to the models and hence improve the precision of 
the estimates of treatment difference. The assumptions 
underlying the ANCOVA technique were checked against these 
data and were not found to be violated. For AER and 
quantitative protein, however, the changes from baseline were 
found to violate the normality assumption underlying the 
ANCOVA technique as they were heavily skewed with extreme 
outliers even after logarithmic transformation. Therefore 
the non parametric Mann Whitney U test was applied to the 
untransformed changes from baseline for these endpoints. 
All analyses were performed using the SAS statistical package 
on an IBM mainframe computer. 
11.3. RESULTS 
Fourteen patients were randomised to each group. 
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Two subsequently withdrew from the lisinopril group [one with 
a history of ischaemic heart disease suffered a fatal 
myocardia1 infarction, one developed ankle oedema] hence 
results in treatment comparisons are based on 12 lisinopril 
versus 14 nifedipine treated patients. The groups were well 
matched for age, weight, sex distribution, and diabetic 
treatments [Table 11.1]. The mean age of the females [38.8 
years] was less than that of the males [55.5 years]. The 
sex imbalance between groups, however, was consistent so it 
was unnecessary to adjust for this in the statistical 
analyses. 
11.3.1. Plasma biochemistry and glycaemic control 
Only small changes within each group and small 
differences between groups were observed for plasma levels of 
sodium, potassium, albumin, creatinine, or urea. Random blood 
glucose and were constant in both groups throughout the 
study and there were no differences between the groups [Table 
11.2]. 
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11.3.2. Haematology 
Haemoglobin fell in the lisinopril group from 
143.2 ± 17.2 g to 138.2 ± 15.5 g at the end of the 
study. Haematocrit did not alter [0.43 ± 0.04 and 0.41 ± 0.04 
respectively]. Neither haemoglobin nor haematocrit altered 
appreciably in the nifedipine group [139.0 ± 16.6 g and 
137.8 ± 20.7 g and 0.42 ± 0.05 and 0.42 ± 0.06]. 
11.3.3. Blood pressure. 
The mean [± SD] dose of lisinopril being taken at 
visit 7 was 15.0 [6.7] mg and of nifedipine was 25.7 [13.4] 
mg. Blood pressure [mean ± SD] was lower in both groups at 
visit 7 compared with visit 2 [143/88 ± 17/13 mm Hg vs 166/99 
± 23/9 mm Hg for lisinopril treated, and 148/85 ± 25/10 mm 
Hg vs. 165/99 ± 21/7 mm Hg for nifedipine treated, Table 
11.3]. Blood pressures were not significantly different 
between groups at the beginning or end of the study [Fig 
11.2]. 
11.3.4. Proteinuria. 
The quantitative urinary protein excretion fell 
[from 551.7 ± 768.7 mg to 473.1 ± 660.8 mg L-I] as did 
albumin excretion rate [from 738.7 ± 635.2 to 644.6 
± 965.2 between visits 2 and 7 respectively in the 
lisinopril treated group. The nifedipine treated group showed 
slight increases in quantitative urinary protein excretion 
[498.4 ± 465.2 mg vs. 554.6 ± 521.9 mg and albumin 
excretion rate [1072.5 ± 908.5 vs. 981.2 ± 1022.2 
between visits 2 and 7 [Fig 11-3]. The difference 
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between treatments, however, was not statistically 
significant for change in AER or for change in quantitative 
urinary protein excretion [Table 11.4]. 
The fractional albumin clearance [ratio urinary 
albumin clearance:glomerular filtration rate] rose between 
visits 2 and 7 from 0.62 ± 0.83 to 0.36 ± 0.41 in the 
nifedipine treated group and fell from 0.22 ± 0.26 to 0.35 ± 
0.41 in the lisinopril treated group. The difference 
between treatment groups for change from baseline was not 
found to be significant [Table 11.41. 
11.3.5. Renal Function. 
GFR fell from 105.2 ± 57.5 ml 1.73 to 
72.1 ± 39.4 m l  1.73 for lisinopril treated, and 
from 108.9 ± 50.0 ml 1.73 to 82.9 ± 53.9 ml 
1.73 for nifedipine treated groups. RBF fell from 446.8 
± 217.9 ml 1.73 to 435.1 ± 243.3 ml 1.73 
for lisinopril treated, and from 473.0 ± 216.4 ml 1.73 
to 419.0 ± 278.6 ml 1.73 for nifedipine treated 
groups between visits 2 and 7 respectively. ERPF fell from 
253.4 ± 118.7 ml 1.73 to 251.6 ± 133.3 ml 
1.73 for lisinopril treated, and from 253.7 ± 97.1 ml 
1.73 to 240.9 ± 143.9 ml 1.73 for 
nifedipine treated groups between visits 2 and 7 
respectively. The differences between groups were not 
significant [Table 11.5]. Filtration fraction [GFR/ERPF] 
fell in the lisinopril treated group [from 0.44 ± 0.14 to 
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0.31 ± 0.12 at visit 7] and did not alter in the nifedipine 
treated group [0.43 ± 0.14 and 0.38 ± 0.17 at visits 2 and 7 
respectively]. Total renal resistance [MAP/ERPF] was 
unaltered in the lisinopril treated group [0.60 ± 0.0.30m Hg 
at visit 2 vs. 0.55 ± 0.31 mm Hg at 
visit 7] but rose in the nifedipine treated group [0.57 ± 
0.30 mm Hg at visit 2 to 0.64 ± 0.47 mm Hg ml-* 
at visit 7]. Inter-group differences for FF and RR 
were not significant. 
11.4. DISCUSSION 
Several studies have demonstrated that treatment 
of hypertension delays the rate of deterioration of renal 
function in diabetic nephropathy [Mogensen 1982, Parving et 
al 1983, 1988b, 1989al. Some of the commonly prescribed 
classes of antihypertensive agents may not, however, be 
suitable in patients with diabetic renal disease. Diuretics 
and ß-blockers may worsen glucose tolerance and have 
unfavourable effects on serum lipid profiles as well as 
provoking impotence. Calcium channel blockers and ACE 
inhibitors have better side effect profiles and some studies 
suggest that ACE inhibitors have beneficial effects on renal 
function in man and animals, lowering intra-renal presures, 
reducing proteinuria and ameliorationg histological changes 
in diabetes [Anderson et al 1986, Zatz et al 1986, Cooper et 
al 1989, Björck et al 1986, Marre et al 1988]. A recently 
published multicentre study reported enalapril to be better 
than metoprolol in reducing AER and preserving renal function 
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and suggested an intrinsic renal action for ACE inhibitors 
[Björck et al 1992]. There are, however, few other studies 
which have compared drugs in this condition. 
11.4.1. Size of study and design 
I have performed a randomised double blind study 
comparing the effects of an ACE inhibitor, lisinopril, and a 
calcium channel blocker, nifedipine, on blood pressure and 
renal function in diabetic patients with hypertension and 
macroproteinuria. Patients were selected carefully to 
exclude those with renal disease of non-diabetic origin and 
those taking medications or diets known to interfere with 
renal function. 
Prolonged tight glycaemic control may prevent the 
development of diabetic nephropathy [Feldt-Rasmussen et al 
1991] but there is no evidence of benefit in established 
renal disease. In this study there was no effect of either 
drug on glycaemic control. 
11.4.2. Blood Pressure 
I used staged increases in the doses of 
antihypertensive agents as recommended in a recent concensus 
document [Working Group on Hypertension in Diabetes Mellitus 
1987]. Both drugs caused significant reductions in systolic 
and diastolic blood pressures at the end of the study and 
mean diastolic blood pressure was less than 90 mm Hg in both 
treatment groups. 
11.4.3. Reduction in Proteinuria 
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Protein excretion was reduced in the lisinopril 
treated group but the nifedipine treated group showed a 
slight increase at the end of the study. Reductions in 
albumin excretion rate have been reported in normotensive and 
hypertensive diabetic patients during ACE inhibitor 
treatment [Marre et al 1988, Björck et al 1990, Mathiesen et 
al 1991]. In a short, open cross-over study Holdaas et al 
[1991] found reduced albumin excretion rate in lisinopril 
treated patients but no change in nifedipine treated 
patients. Alterations in proteinuria are thought to depend 
upon changes in intra-renal haemodynamics [Anderson et al 
1986]. ACE inhibitors act primarily on the efferent renal 
arteriole and reduce intra glomerular pressure; this in turn 
reduces filtration pressure across the glomerular capillary 
basement membrane and so reduces protein filtration. 
11.4.4. Renal Haemodvnamics 
GFR fell in both groups but the data in the 
lisinopril treated group were heavily skewed by one patient's 
results which fell from 277 ml 1.73 to 91 ml 
1.73 Some of the patients must have been entering the 
stage of nephropathy when renal function begins to 
deteriorate and since pre-trial GFRs were not measured it is 
impossible to tell whether antihypertensive medication 
influenced rates of decline. Baba et al [1989] reported no 
change in GFR or ERPF in a study comparing nicardipine with 
enalapril in similar patients. 
There was no change in renal resistance in the 
lisinopril treated group although there was a small rise in 
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the nifedipine treated group, perhaps explained by the 
greater fall in RBF. The filtration fraction fell in 
lisinopril but not nifedipine treated patients compatible 
with the facts that ACE inhibitors exert their predominant 
intra-renal effect on the efferent glomerular arteriole 
whilst calcium channel blockers act at the afferent 
arteriole [Lutzenhiser and Epstein 1985]. Fractional 
albumin clearance fell in the lisinopril treated group 
despite the reduction in GFR. Although the fall in GFR in 
the nifedipine treated group was of comparable magnitude 
there was an increase in fractional albumin clearance. This 
suggests that lisinopril may exert a specific intra-renal 
effect on protein handling independent of alterations in 
renal haemodynamics. 
11.4.5. Conclusions 
In this study both the ACE inhibitor lisinopril 
and the calcium channel blocker nifedipine reduced blood 
pressure equally with no significant intergroup differences 
in renal haemodynamics or proteinuria. There were, however, 
large confidence intervals for the observed changes in each 
of the measured variables. There was a trend for albumin 
excretion rate to fall in the ACE inhibitor group and rise in 
the calcium blocker group and the two groups appeared to be 
diverging at the end of the study. This may be the 
consequence of differing intra-renal actions of the two 
classes of drug. Reduced fractional albumin clearance in the 
ACE inhibitor group suggests that this drug may have an 
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intra-renal effect distinct from its effects on 
haemodynamics. Longer studies with larger patient numbers are 
required to answer this question. 
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CHAPTER 12 
STUDIES OF 
ON RENAL FUNCTION AND PROTEINURIA 
ANGIOTENSIN CONVERTING ENZYME [ACE] INHIBITION 
IN DIABETES MELLITUS 
2. INCIPIENT NEPHROPATHY 
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12.1.INTRODUCTION 
The rate of decline of renal function in patients 
with established diabetic nephropathy may be slowed by 
control of hypertension using a variety of drugs [Mogensen 
1982, Parving et al 1987]. Recent data, however, suggest that 
angiotensin converting enzyme [ACE] inhibitors may be 
particularly suitable agents for control of blood pressure in 
diabetic renal disease. Animal studies have shown that ACE 
inhibitors decrease proteinuria and may ameliorate the 
histological changes of diabetic nephropathy [Anderson et al 
1986, Zatz et al 1986] and studies in human diabetic 
nephropathy [albumin excretion rate [AER] 200 
suggest that ACE inhibition is beneficial, perhaps having a 
specific intra-renal effect [Mathiesen et al 1991, Björck et 
al 1992, Marre et al 19883. 
Before entering the stage of frank nephropathy 
[AER > 200 and systemic arterial hypertension] 
patients pass through a phase of incipient nephropathy [AER 
20 but 200 when they are still 
normotensive. Interest has focussed recently on the intra 
renal effects of ACE inhibitors and their potential use in 
this phase of diabetic nephropathy. Two studies have reported 
protection of renal function with ACE inhibitors in such 
patients [Mathiesen et al 1991, Marre et al 1988]. Renal 
hyperfiltration in the early stages of diabetic nephropathy 
is well recognized and may depend in part upon intra renal 
prostaglandins [Esmatjes et al 1985, Gambardella et al 1988] 
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although this view has been challenged [Barnett et al 1987, 
Jenkins et al 1989]. Mathiesen et al [1988] and Hommel et al 
[1987], however, have demonstrated altered urinary 
prostaglandin excretion in established and incipient 
diabetic nephropathy. Both these workers, and earlier 
Barnett et al [1984], demonstrated that diabetic proteinuria 
could be reduced by drugs which interfere with prostaglandin 
synthesis. I have studied the effects of ACE inhibition with 
lisinopril on renal function, urinary prostaglandin excretion 
and albumin excretion rate in patients with incipient 
diabetic nephropathy. 
12.2. SUBJECTS AND METHODS. 
Male and female patients aged 18-70 years with 
type 1 or Type 2 diabetes mellitus and incipient diabetic 
nephropathy were recruited from the diabetic-renal clinic. 
All had resting diastolic blood pressure 90 mm Hg. 
Exclusion criteria were the same as the previous 
study [Chapter 11.2] except for the following: hypertension 
of any aetiology: plasma creatinine 140 Patients 
fulfilling the inclusion criteria gave informed consent and 
then followed the study protocol as detailed in Figure 12.1. 
All patients entered the two week placebo run in 
period to assess compliance [Visit i]. Tablets were counted 
at visit 2 and those whose compliance was less than 80% were 
excluded were excluded from final data analysis. Patients 
were then randomised double blind to receive lisinopril or 
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placebo according to separate schedules for type 1 and type 
2 diabetes. Patients randomised to receive lisinopril were 
given a test dose of 2.5 mg. All patients were reviewed the 
following day and if the test dose had been tolerated the 
lisinopril group continued on 10 mg daily and the placebo 
group with matching placebo for the duration of the study [48  
weeks]. 
Patients were reviewed on four further occasions 
at 12 week intervals. At each visit, after at least 10 
minutes rest, blood pressure was measured twice in the right 
arm, at heart level, using a Hawksley random zero 
sphygmomanometer and the mean of these readings was recorded. 
There was provision in the study protocol for  open treatment 
with nifedipine of patients who developed diastolic blood 
pressure 95 mm Hg. One patient in each group required this 
intervention. At each visit mean arterial blood 
pressure [MAP] was calculated as diastolic blood pressure 
+ pulse pressure/3. The radial pulse was counted for one 
minute to measure heart rate. 
12.2.1. Renal Function. 
Glomerular filtration rate [GFR] and renal blood 
flow [RBF] were measured at visits 2, 5 and 7. 
12.2.2. Proteinuria 
Timed overnight urine collections were made on 
the three consecutive days immediately prior to visits 1, 2, 
4 ,  and 7. Albumin concentration was measured in the 
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three samples and AER was calculated using the formula; 
AER = CV 
T 
[where C is the urinary albumin concentration, V is the 
volume of urine passed during the collection and T is the 
duration of the collection]. 
The mean of the three values for each visit was calculated. 
12.2.3. Urinary Prostaqlandins 
Aliquots of urine were taken from the third of the 
timed overnight collections, frozen at -70 xC and assayed in 
a single batch by radio-immunoassays for content of 
prostaglandin-Fl [PGFl and thromboxane-B using 
commercially available kits [Amersham]. 
12.2.4. Haematology and Biochemistry 
Blood was taken at visits 2 and 7 for measurement 
of haemoglobin and haematocrit, and at visits 2, 4, 5 and 
7 for measurement of albumin, creatinine, urea, sodium, and 
potassium, plasma glucose and glycated haemoglobin 
reference range 5.0-9.0%]. 
12.2.5. Statistical analysis. 
Primary end points for the study were changes in 
AER, urinary prostaglandins, GFR and RBF after 48 weeks 
treatment. Secondary end points were changes in heart rate, 
blood pressure and metabolic control. Changes from baseline 
[visit 2] to the end of randomised treatment [visit 7] were 
analysed using the analysis of covariance [ANCOVA] technique. 
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The baseline values were further included in the model since 
this was found to contribute substantially to the model and 
hence improve the precision of the estimate of treatment 
difference. The assumptions underlying the ANCOVA technique 
[normality and homoscedasticity] were checked against the 
data and found not to be violated. Patients whose 
compliance was less than 80% were excluded from the final 
analyses. All analyses were performed using the SAS 
statistical package on an IBM mainframe computer. 
12.3. RESULTS 
Thirty-two patients entered the study: 15 were 
randomised to lisinopril and 17 to placebo. Three 
lisinopril treated patients were withdrawn, 2 because of 
adverse effects [cough, skin rash] and 1 because of failure 
to attend. Two placebo treated patients were withdrawn, 1 
because of adverse effects [diabetic keto-acidosis and 
pulmonary oedema] and 1 for failure to attend. Hence, 27 
patients completed the study and descriptive data are 
presented for these. Four patients violated the study 
protocol hence statistical analyses of treatment differences 
were performed on data from the remaining 23 [11 lisinopril, 
12 placebo]. The groups were well matched for age, sex, 
weight and treatment of diabetes [Table 12.1]. 
12.3.1. Proteinuria. 
Mean [±SD] AER fell in the lisinopril groups from 
57.6 ± 25.7 [n=15] at baseline to 26.8 ± 26.7 
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[n=12] after 48 weeks treatment but was unaltered in 
the placebo group 119.2 ± 116.6 [n=17] vs. 113.7 ± 
77.0 pg min-' [n=15]. There was a least squares mean change 
from baseline of -30.1 for the lisinopril and +37.5 
for the placebo groups giving a treatment difference 
of -67.6 [95% CI, -115.0 to -20.2, P < 0.01] in 
favour of lisinopril. After 48 weeks treatment 7 lisinopril 
treated patients were normoalbuminuric and 5 were 
microproteinuric; 3 placebo treated were normoalbuminuric, 9 
microalbuminuric and 3 were macroproteinuric [Fig 12.2]. 
12.3.2. Urinary Prostaqlandins 
Urinary excretion of both and fell 
during treatment in both groups although the fall was greater 
for lisinopril [Table 12.2]. The treament differences between 
lisinopril [n=9] and placebo [n=8] groups, however, were 
insignificant [-18.9 pg min'=, 95% CI -138.6 to 100.9, P = 
0.74 for and -105.4 pg min", 95% CI -385.2 to 174.4, P 
= 0.43 for TXBz]. 
12.3.3. Renal Function. 
GFR fell in both groups during the study from 
126.9 ± 46.7 [n=15] to 100.8 ± 27.4 ml [n=12] 
for lisinopril treated patients and from 110.8 ± 34.0 [n=17] 
to 103.1 ± 38.3 ml [n=15] for placebo treated 
patients [Fig 12.3]. There was a 15.7 ml [95% 
CI -41.5 to 10.1, P = 0.22] larger mean decrease in the 
lisinopril group [n=11] than in the placebo group [n=12] but 
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this was not statistically significant. 
ERPF fell in the lisinopril group from 323.1 ± 
120.4 [n=15] to 304.7 ± 115.1 ml [n=12] and 
rose in the placebo group from 312.6 ± 135.8 [n=17] to 349.6 
± 189.4 ml [n=14]. There was a treatment 
difference of -68.5 m l  [95% CI -173.6 to 36.7, 
P = 0.19] in favour of lisinopril treated patients. 
Filtration fraction fell slightly in both groups 
[from 0.40 ± 0.09 [n=15] to 0.35 ± 0.10 [n=12] for 
lisinopril, and from 0.38 ± 0.11 [n=17] to 0.33 ± 0.11 [n=14] 
for placebo] but there was no difference between the groups 
[treatment difference 0.00, 95% CI -0.09 to 0.10, P = 0.91]. 
Renal resistance did not alter in either group 
0.34 ± 0.13 mm Hg [n=15] and 0.34 ± 0.12 mm Hg ml- 
1 [n=12] for lisinopril, 0.37 ± 0.18 mm Hg 
[n=17] and 0.35 ± 0.20 mm Hg [n=14] for placebo. 
There was no difference between groups [treatment difference 
0.04, 95% CI -0.06 to 0.13, P = 0.42]. 
12.3.4. Heart rate and Blood Pressure 
Heart rate did not alter significantly from 
baseline in either group 178.5±13.9 beats [n=15] at 
visit 2 and 80.5±11.8 beats [n=12] at visit 7 for 
[n=17] and lisinopril treated and 80.9±10.4 beats 
79.9±8.4 beats [n=15] for placebo treated]. There was 
no difference between groups [1.3 beats 95% CI -7.7 to 
10.3, P = 0.77]. Systolic blood pressure fell in the 
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lisinopril group from 136 ± 20 mm Hg [n=15] to 125 ± 19 mm Hg 
[n=12] but did not alter in the placebo group, 136 ± 26 mm Hg 
[n=17] and 138 ± 23 mm Hg [n=15]. The treatment difference 
was not significant [12 mm Hg, 95% CI -27 to 3, P = 0.1]. 
Diastolic blood pressure did not alter appreciably in either 
group [from 78 ± 10 mm Hg at visit 2 to 78 ± 13 mm Hg at 
visit 7 for lisinopril, and from 77 ± 9 mm Hg to 74 ± 15 mm 
Hg for placebo groups. 
12.3.5. Biochemistry and Glycaemic Control 
Random glucose fell by 3.3 mmol in the 
lisinopril group [n=11] and rose in the placebo group [n=9] 
by 3.9 mmol giving a treatment difference of -7.2 mmol 1- 
1 [95% CI - 1 3 . 3  to -1.2, P < 0.02] in favour of lisinopril. 
GHb fell by 2.6% in the lisinopril [n=11] group and 0.8% in 
the placebo group [n=11] but this -1.8% difference [95% CI - 
4.0 to 0.4, P = 0.11] was not significant. There were no 
large differences within or between groups for any other 
variable [Table 12.3]. 
12.3.6. Haematology 
Haemoglobin and haematocrit did not alter 
appreciably in either group between visits 2 and 7 [from 147 
± 17 g and 0.44 ± 0.04, to 144 ± 15 g and 0.43 ± 0.05 
for lisinopril, and from 142 1: 20 g and 0.42 ± 0.06 to 
140 ± 20 g and 0.42 ± 0.06 for placebo]. 
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1 2 . 4 .  DISCUSSION 
Results from studies in animals and humans have 
suggested that ACE inhibitors exert specific intra-renal 
effects in diabetic nephropathy [Anderson et al 1986, Zatz et 
al 1986, Mathiesen et al 1991, Marre et al 1988]. Two 
studies have reported that treatment with ACE inhibitors 
postpones the development of overt diabetic nephropathy. 
Marre et al [1988] found that after 12 months treatment with 
enalapril 5 patients remained microalbuminuric and 5 were 
normoalbuminuric whereas 3/10 patients taking placebo had 
developed diabetic nephropathy. Mathiesen et al [1991] 
reported an open multicentre study in which nephropathy 
developed in 7/23 patients given placebo for 4 years but, in 
none of the 21 patients treated with captopril and thiazide. 
I performed a double blind placebo controlled single centre 
study involving 27 patients and found that 7 lisinopril 
treated patients became normoalbuminuric and 5 remained 
microalbuminuric; none developed nephropathy. Three placebo 
treated patients became normoalbuminuric, 9 remained 
microalbuminuric and 3 developed nephropathy. Hence I can 
confirm the renal protective effect of ACE inhibition in 
incipient diabetic nephropathy. The reduction in proteinuria 
in the lisinopril treated group appears to be independent,of 
alterations in systemic blood pressure and this observation 
supports other workers' reports of a specific intra-renal 
effect of ACE inhibitors [Anderson et al 1986, Zatz et al 
1986, Mathiesen et al 1991, Marre et al 1988]. The 
mechanism whereby ACE inhibitors exert this effect is thought 
to be efferent arteriolar dilatation causing a reduction in 
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intraglomerular hypertension [Anderson et al 1986, Zatz et al 
1986]. 
Glomerular filtration rate fell in both groups. 
In patients eligible for analysis of treatment difference the 
average fall was -29 ml for lisinopril treated 
patients and -13.4 ml for those on placebo. 
These falls are larger than reported by Marre et al [1988] or 
Mathiesen et al [1991] and may relate to methodological 
differences or the different population under study. It is 
perhaps noteworthy that 5 patients in the lisinopril group 
but only 1 in the placebo group were hyperfiltering [GFR >160 
ml at entry to the study and the greatest 
reductions in GFR were seen in these [Fig 12.3]. It is known 
that hyperfiltering diabetic patients experience a fall in 
GFR as their disease progresses. My patients may have been at 
this stage of their disease and the apparent difference 
between groups may have been a consequence of this rather 
than a drug effect. I could demonstrate no benefit of ACE 
inhibition over placebo on any other aspect of renal 
haemodynamics. A similar lack of benefit from ACE inhibition 
on renal function has been described in hyperfiltering 
normoalbuminuric diabetic children treated with enalapril 
[Drummond et al 1989]. 
It has been reported that both specific 
thromboxane synthetase inhibition and treatment with 
indomethacin, a cyclooxygenase inhibitor, may reduce 
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proteinuria in established and incipient diabetic nephropathy 
in association with altered urinary prostaglandin 
excretion [Barnett et al 1984, Hommel et al 1987, Mathiesen 
et al 1988]. The precise mechanism underlying this reduction 
is unclear but it may be a consequence of prostaglandin 
mediated alterations in intra renal haemodynamics or on 
glomerular mesangial cells reducing the surface area 
available for filtration. I found no difference between 
groups for urinary excretion of a 
metabolite of the vasodilator prostacyclin, or of 
the metabolite of vasoconstrictor 
Although the confidence intervals for  the 
differences between placebo and active treatment groups are 
wide these data suggest that the effects of ACE inhibition on 
proteinuria are not prostaglandin mediated. 
In summary, I have demonstrated a renal protective 
effect of ACE inhibition in patients with incipient diabetic 
nephropathy in a single centre double blind placebo 
controlled study. The observed reductions in proteinuria 
appear to be independent of changes in systemic blood 
pressure. Alterations in urinary protein excretion do not 
depend upon changes in renal prostaglandin activity. In 
these patients lisinopril appeared to be no more renal 
protective than placebo. The study population, however, was 
small and a larger number of patients is required to provide 
a definitive answer. 
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CHAPTER 13. 
CONCLUSIONS 
AND SUGGESTIONS FOR 
FURTHER RESEARCH 
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CONCLUSIONS - PART I 
Initial data from several workers suggested that 
urinary transferrin may be a useful marker for complications 
of diabetes mellitus and a predictor of diabetic renal 
disease. I have examined these claims in a series of cross- 
sectional, longitudinal and interventional clinical studies. 
1 3 . 1 .  PREVALENCE OF PROTEINURIA 
I have examined a defined population of type 1 
diabetic patients and established that the prevalences of 
diabetic renal disease [defined by albumin excretion rate] 
and associated complications are similar to those reported by 
other investigators. There is an increased prevalence of 
retinopathy with increasing albuminuria and, similarly, an 
increased prevalence of hypertension. I could not confirm 
previous workers' reports of an association between cigarette 
smoking and diabetic nephropathy; this may relate to the 
crude method chosen to measure smoking habit. 
13.2. PREVALENCE OF TRANSFERRINURIA 
I established a reference range for urinary 
transferrin excretion based upon a group of 28 non-diabetic 
subjects. Transferrin excretion appears to be unrelated to 
sex or age in this group. Study of the patient population 
defined in chapter 4 established that transferrin and albumin 
are handled differently in the diabetic kidney; 85% of 
diabetic patients had elevated transferrin excretion compared 
with only 38% who had elevated albumin excretion rate. Al 1 
diabetic patients with elevated albumin excretion rate had 
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elevated transferrin excretion. 
13.3. EFFECTS OF GLYCAEMIC CONTROL ON TRANSFERRINURIA 
Newly diagnosed diabetic patients are known to 
have increased albumin excretion rates. I have demonstrated 
that they also have increased urinary transferrin excretion 
rates. The transferrin excretion rates are correlated with 
markers of tubular function suggesting that the renal tubules 
may be important in the handling of transferrin in diabetes. 
I could not confirm other workers observations of an 
association between increased urinary transferrin excretion 
and the presence of diabetic complications. 
13.4. EFFECT OF EXERCISE ON TRANSFERRINURIA 
I have shown that urinary transferrin excretion 
may be provoked by moderate exercise in type 1 diabetic 
patients with no evidence of complications. This obceration 
is novel. The mechanism for the increased proteinuria 
remains to be elucidated. It may, however, relate to 
increased glomerular leak rather than altered tubular 
handling of transferrin since there was no alteration in 
other markers of renal tubular function in this study. The 
data suggest that even patients with apparently uncomplicated 
diabetes mellitus may have abnormal renal function. 
13.5. THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITION 
ON TRANSFERRINURIA 
I have demonstrated in two studies that 
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angiotensin converting enzyme [ACE] inhibition in diabetic 
patients may influence transferrin excretion. The first was 
a study of normotensive patients with microalbuminuria. 
Patients treated with an ACE inhibitor tended to have a 
reduction in transferrin excretion rates. The second was a 
study of hypertensive macroalbuminuric patients. Those 
treated with an ACE inhibitor had reduced transferrin 
excretion which was independent of reductions in systemic 
blood pressure. The reduction in excretion is probably 
accomplished by lowering of intraglomerular pressure. 
CONCLUSIONS - PART II 
13.6. ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 
Patients with elevated albumin excretion rates 
have elevated plasma renin activity but there is no 
correlation between the two variables. Overall there is a 
weak correlation between systolic blood pressure and albumin 
excretion rate but not with plasma renin activity. These 
observations although on a small number of patients suggest 
that altered plasma renin activity is not responsible for 
the hypertension seen in diabetic nephropathy. 
13.7. RESPONSE OF RENIN-AGIOTENSIN-ALDOSTERONE SYSTEM AND 
BLOOD PRESSURE TO EXERCISE 
-Exercise provokes an exaggerated systolic 
blood pressure response and reduction in urinary sodium 
excretion in normoalbuminuric type 1 diabetic patients. Both 
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findings may reflect increased sensitivity to the renin- 
angiotensin-aldosterone system despite normal plasma renin 
activity levels. The highest blood pressure changes were 
associated with an enhanced noradrenaline response despite 
lower basal levels in the diabetic group. Reduced atrial 
natriuretic peptide levels may stimulate sodium retention and 
increased diastolic blood pressure in early type 1 diabetes 
mellitus. The presence of these changes in a group of 
otherwise uncomplicated type 1 diabetic subjects suggests 
they are a consequence of the diabetic state rather than the 
development of micro- or macrovascular complications. 
13.8. AN GIOTENSIN CONVERTING ENZYME INHIBITION IN OVERT 
DIABETIC NEPHROPATHY 
In a randomised double blind single centre 
study comparing an ACE inhibitor, lisinopril, with a calcium 
channel blocker, nifedipine, for 6 months in diabetic 
patients with hypertension and macroproteinuria both drugs 
reduced blood pressure equally. There were no significant 
intergroup differences in renal haemodynamics or proteinuria. 
There was, however, a trend for albumin excretion rate to 
fall in the ACE inhibitor group and rise in the calcium 
blocker group and the two groups appeared to be diverging at 
the end of the study. This may be the consequence of 
differing intra-renal actions of the two classes of drug. 
Reduced fractional albumin clearance in the ACE inhibitor 
group suggests that this drug may have an intra-renal effect 
distinct from its effects on haemodynamics. 
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13.9. ANGIOTENSIN CONVERTING ENZYME: INHIBITION IN INCIPIENT 
DIABETIC NEPHROPATHY 
In a randomised double blind single centre 
study comparing an ACE inhibitor, lisinopril, with placebo 
for 12 months in diabetic patients with normotension and 
microproteinuria glomerular filtration rate fell in both 
groups. No lisinopril treated patients progressed to 
macroproteinuria but three placebo treated did. Hence it 
appears that ACE inhibition offers some renal protection in 
this patient group. The observed reductions in proteinuria 
appear to be independent of changes in systemic blood 
pressure and not to depend upon renal prostaglandin activity. 
13.10. SUGGESTIONS FOR FURTHER RESEARCH 
In the cross sectional study 85% patients had elevated 
transferrin excretion rates and all patients with elevated 
albumin excretion rates had elevated transferrin excretion 
rates. The high prevalence of elevated tansferrin excretion 
rate [as presently defined] makes this a poor predictor of 
diabetic nephropathy. It is proposed to follow the original 
patient population longitudinally to assess changes in 
albumin and transferrin excretions. This will allow the 
identification of new cases of elevated albumin excretion and 
perhaps permit identification of an initial transferrin 
excretion rate which is predictive of nephropathy. 
Some data suggest that renal handling of 
transferrin is dependent upon tubular rather than glomerular 
function. To elucidate the true mechanism it is proposed to 
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observe alterations in urinary transferrin excretion after 
blocking renal tubular re-uptake with intravenously infused 
lysine. 
Whilst they did not show a clear difference the 
results of the study comparing the effects of nifedipine and 
lisinopril in patients with overt nephropathy suggested that 
there may have been some difference between the two after six 
months. A longer term study using a similar protocol may 
resolve this question. 
The question of whether or not ACE inhibitors are 
truly renal protective in diabetes remains unresolved and 
long term studies [5 to 10 years duration] are required to 
answer this definitively. 
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ADDENDA 
ADDENDUM I. 
ABBREVIATIONS 
ACE Angiotensin converting enzyme 
AER Albumin excretion rate 
ANCOVA Analysis of covariance 
ANP Atrial natriuretic peptide [factor] 
Alpha-1-microglobulin 
BP Blood pressure 
ECG Electrocardiogram 
EDTA Ethylene diamine tetra-acetic acid 
ERPF Effective renal plasma flow 
FF Filtration fraction 
GFR Glomerular filtration rate 
Glycated haemoglobin 
MAP Mean arterial pressure 
NAG N-acetyl-ß-D-glucosaminidase 
Prostaglandin 
Prostaglandin 
Prostaglandin 
Prostaglandin [Prostacyclin] 
PRA Plasma renin activity 
RAAS Renin angiotensin aldosterone 
RBF Renal blood flow 
RIA Radio-immunoassay 
RR Renal resistance 
SD Standard deviation 
SNGFR Single nephron glomerular 
system 
filtration rate 
TER Transferrin excretion rate 
Tubular maximum reabsorption 
capacity for glucose 
Thromboxane 
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